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 ABSTRACT 
Primary Sjögren’s syndrome (pSS) is a systemic inflammatory autoimmune 
condition. The etiology of pSS is mainly unknown, but it has been suggested 
that environmental factors trigger an immune response in genetically 
susceptible individuals. The disease is characterized by chronic inflammation 
which results in progressive destruction of exocrine glands, primarily the 
salivary and lacrimal glands, leading to symptoms of dryness, mainly in the 
mouth and eyes. Patients may also experience symptoms of exocrine 
dysfunction and dryness in other parts of the body. Autoantibodies against the 
antigens Ro/SSA (Ro52 and Ro60) and La/SSB, are a well-known sign of 
dysregulation of the immune system. Extraglandular manifestations (EGM) are 
present in a subset of patients with pSS.  
In a population based prospective study we included all patients referred to the 
Department of Rheumatology for suspected pSS during a five-year period. The 
patients were evaluated using a structured procedure according to the 2002 
Revised American-European Consensus Criteria for Sjögren’s syndrome. Of 
referred individuals, 199 of 781 patients were diagnosed with pSS. We found 
an annual incidence rate of pSS in the Karolinska University Hospital 
catchment area of 3.1 (95% CI 2.3-4.3) cases per 100,000 adult inhabitants. In 
this cohort, we noted lower figures for severe EGM such as lung and 
neurological involvement than previously reported for prevalent pSS. Also, the 
frequency of autoantibodies including ANA, anti-Ro/SSA and anti-La/SSB 
was lower compared to other cohorts. Subsets of these patients were recruited 
and included in genetic studies. 
We contributed with 79 pSS patients in a candidate-gene association case 
control study in 540 patients with pSS and 532 controls, from Sweden and 
Norway. Three novel gene loci, not previously associated with pSS, were 
identified: the early B-cell factor 1 (EBF1) gene, the family with sequence 
similarity 167 member A–B-lymphoid tyrosine kinase (FAM167A–BLK) 
locus, and the tumor necrosis factor superfamily (TNFSF4=Ox40L) gene. 
Variations in the gene loci for interferon regulation factor 5 (IRF5) and signal 
transducer and activator of transcription 4 (STAT4) were confirmed. The three 
novel gene variants are involved in B-cell development and activation.  
In an international multicenter case control genome-wide association study 
(GWAS)/ large-scale association study of pSS, we contributed with 99 patients. 
The results confirmed associations with variations in the gene loci of the 
human leukocyte antigen (HLA) region, IRF5, STAT4, FAM167A-BLK, 
chemokine C-X-C motif receptor 5 (DX6-CXCR), and TNFAIP3 interacting 
protein 1 (TNIP1) at a genome-wide significance level. In addition, 29 further 
suggested associations (p meta < 5 × 10−5) were observed. The major part of 
these genes is involved in both innate and adaptive immune responses.  
We observed that the autoantigen Ro52 was expressed and upregulated in 
salivary glands of patients with primary Sjögren’s syndrome. This was noted in 
biopsies from 28 pSS patients and 19 non-pSS controls from Sweden and 
Norway. The degree of expression was correlated with the level of 
inflammation in the tissue.  
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease 
characterized by multiple organ manifestations and immunological 
dysregulation including production of a large set of autoantibodies targeting 
different epitopes. We showed that antibodies to the RING domain of Ro52, 
which is the functionally active domain with E3 ligase activity, were 
significantly correlated with disease activity as measured by the SLAM score 
in a well-characterized cohort of SLE patients. 
In conclusion, the results of these studies have highlighted the role of the 
immune system in the pathogenesis in pSS and SLE. 
  
 SVENSK SAMMANFATTNING 
Primärt Sjögren’s syndrom (pSS) är en systemisk autoimmun inflammatorisk 
sjukdom. Etiologin till pSS är huvudsakligen okänd, men hypotesen är att 
miljöfaktorer utlöser en immunologisk reaktion i genetiskt predisponerade 
individer. Sjukdomen karakteriseras av kronisk inflammation som progressivt 
destruerar exokrina körtlar. Mest drabbade är saliv- och tårkörtlar, vilket leder 
till symtom med torrhet, s.k. sicca symtom, i främst mun och ögon. Patienterna 
kan uppleva sicca symtom även i andra delar av kroppen orsakad av exokin 
dysfunktion. Autoantikroppar mot antigenerna Ro/SSA (Ro52 och Ro60) och 
La/SSB, är ett tecken på förändrad reglering av immunförsvaret. Extraglandular 
manifestationer (EGM), förekommer hos en del patienter med pSS.  
I en populations baserad prospektiv studie, inkluderade vi alla patienter som 
remitterades till Reumatologiska kliniken vid Karolinska Universitetssjukhuset 
för utredning av pSS under fem års tid. Patienterna utreddes enligt 2002 års 
reviderade Amerikansk-Europeiska Konsensus Kriterierna för Sjögrens 
syndrom. Av 781 remitterade patienter uppfyllde 199 kriterierna för pSS. 
Incidensen beräknades till 3.1 (95% CI 2.3-4.3) fall per 100 000 vuxna invånare 
per år i Karolinska Universitetssjukhusets upptagningsområde. I denna kohort 
noterade vi lägre prevalence siffror för EGM som interstitiell lungsjukdom och 
polyneuropati jämfört med tidigare studier. Frekvensen av autoantikroppar 
såsom ANA, anti-Ro/SSA- och anti-La/SSB var också lägre vid jämförelse 
Vi bidrog med 79 pSS-patienter i en kandidatgen fall-kontrollstudie med totalt 
540 patienter med pSS och 532 kontroller från Sverige och Norge. Tre nya gen-
lokus, som inte tidigare förknippats med pSS, identifierades: the early B-cell 
factor 1 (EBF1) genen, the family with sequence similarity 167 member A–B-
lymphoid tyrosine kinase (FAM167A–BLK) gen-lokus och the tumor necrosis 
factor superfamily (TNFSF4=Ox40L) genen. Genvariation i interferon 
regulation factor 5 (IRF5) och signal transducer and activator of transcription 4 
(STAT4) generna bekräftades. De tre nya genvariationerna ligger i gener som 
deltar i B-cells utmognad och aktivering. 
I en internationell multicenter fall-kontroll studie, en sk genome-wide 
association studie (GWAS), bidrog vi med 99 patienter. Resultaten bekräftade 
tidigare fynd från andra studier, men med en genome-wide signifikansnivå. 
Förändringarna var belägna i HLA regionen, IRF5, STAT4, FAM167A-BLK, 
chemokine C-X-C motiv receptor 5 (DX6-CXCR), och TNFAIP3 interacting 
protein 1 (TNIP1). Dessutom observerades ytterligare 29 genvarianter med lägre 
signifikansnivå (p meta < 5 × 10−5). De flesta av generna är inblandade i det 
medfödda och adaptiva immunförsvaret. 
I en laborativ studie kunde vi konstatera att autoantigenet Ro52 uttryckts och 
uppregleras i spottkörtelvävnad hos patienter med primärt Sjögrens syndrom. 
Detta undersöktes i biopsier från 28 patienter med pSS och 19 kontrollerfrån 
Sverige och Norge. Graden av uppreglering korrelerade med graden av 
inflammation i vävnaden.  
Systemisk lupus erythematosus (SLE) är en kronisk autoimmun sjukdom som 
kännetecknas av multipla organ manifestationer och hög produktion av 
autoantikroppar riktade mot olika epitoper. Vi visade att antikroppar riktade mot 
den s.k. RING domänen av Ro52 proteinet var signifikant korrelerat med ökad 
sjukdomsaktivitet mätt med SLAM (SLE activity measure). Undersökningen 
genomfördes i en välkaraktäriserad kohort av SLE patienter. RING domänen är 
den funktionellt aktiva domänen av Ro52 proteinet med E3 ligase aktivitet vilket 
indikeras en inverkan som hör ihop med Ro52:s  funktion. 
Sammanfattningsvis har resultaten av dessa studier belyst immunförsvarets roll i 
patogenesen vid sjukdomarna pSS och SLE. 
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1 SYSTEMIC AUTOIMMUNE RHEUMATIC 
DISEASES 
1.1 INTRODUCTION 
Rheumatic diseases are traditionally diseases that affect the musculoskeletal system in 
the body. There are approximately a hundred different diseases which are regarded as 
rheumatic. At Rheumatology clinics in Sweden, the focus is on inflammatory 
rheumatic diseases. The different diagnoses can be divided into two main groups; 
polyarthritis and systemic diseases. The systemic rheumatic diseases, also called 
systemic inflammatory diseases partly overlap inflammatory polyarthritis. The 
systemic diseases are regarded as autoimmune (as is polyarthritis), involve more than 
one organ system, and the inflammation involves many organs, tissues and cells 
throughout the body. Most well-known is Systemic Lupus Erythematosus (SLE) 
which is regarded as the prototype autoimmune disease since so many immunological 
disturbances may present in patients with this diagnosis. Other systemic diseases are 
Systemic sclerosis (Scleroderma), primary Sjögren’s syndrome (pSS), Myositis, and 
Systemic Vasculitis. Patients with these diagnoses usually have dominant symptoms 
from one organ system: Systemic sclerosis - the skin (also blood vessels); pSS - sicca 
symptoms from eyes and mouth; Myositis - muscle; Vasculitis - symptoms depend on 
the location of the affected blood vessels. Common general symptoms for all these 
diagnosis can be fever, weight loss, arthralgia, myalgia and fatigue. Laboratory tests of 
blood or urine are used both for diagnosis and checked on a regular basis for control of 
disease activity. Results will generally show signs of inflammation in the body: 
increased erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), 
anemia, increased or decreased white blood cell count, hematuria, and immunological 
disturbances like the presence of different autoantibodies against nuclear antigens: 
antinuclear antibodies (ANA), extractable nuclear antigen (ENA) antibodies and/or 
anti-neutrophil cytoplasmic antibodies (ANCA). All the systemic diseases have their 
own criteria for classification and/or diagnosis. For diagnosis, the combination of 
results from physical examination, laboratory tests and sometimes different 
investigations including x-ray is necessary. Treatment depends on the severity of 
organ involvement and the primary diagnosis. Frequently used therapies are 
corticosteroids and immunosuppressives, Disease Modifying Anti Rheumatic Drugs 
(DMARD). 
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2 ETIOLOGIC FACTORS IN SYSTEMIC 
AUTOIMMUNITY 
The different systemic autoimmune rheumatic diseases have many clinical features in 
common as described above. In recent years, research has found similar etiologic 
mechanisms for these diseases in areas such as genetics, immunology and environmental 
factors. Hence, the two diseases included in this thesis, pSS and SLE, are as far as 
possible presented integrated in the text. 
 
2.1 GENETICS 
During the 20th century science has revealed how genetic information works and is 
inherited. The cellular basis of heredity is chromosomes (46XYin humans) consisting of 
the DNA (Deoxyribonucleic acid) double helix molecule and histones. DNA is built of 
nucleotides with four different nucleobases: adenine, cytosine, guanine and thymine (A, 
C, G and T). The nucleobases form pairs, either A-T or C-G. This sequence of the DNA 
strands provides all genetic information. The biological mechanisms by which cells read 
the information contained in DNA and eventually produce peptides include transcription 
of DNA to messenger-RNA (a single stranded polynucleotide) and translation to 
peptides where the amino acid sequence depends on the nucleotide-sequence (Strachan 
and Read 2011c). The human genome consists of over three billion base-pairs. Scientists 
have been working on the task to decipher first genes, and then the entire human 
genome. The invention of the recombinant DNA technologies with cloning and 
sequencing was used to reveal the human complete DNA sequence i.e. genome (Lander, 
et al. 2001; Venter, et al. 2001). The human genome differs by less than a half percent 
person to person (Kidd, et al. 2008). 
A gene is a molecular unit of DNA, which is inherited, usually coding for a protein. The 
number of protein coding genes is currently 18,683 
(http://www.ncbi.nlm.nih.gov/CCDS, Jan 29, 2013). The genes consist of coding and 
non-coding sequences of DNA. The non-coding parts, which are removed from the 
transcript, are called introns, and can have regulatory functions such as providing 
binding sites for regulatory factors, or acting as promoters where the transcription starts 
(Strachan and Read 2011c). 
Single nucleotide polymorphisms (SNPs) are the most common genetic variations, and 
occur at 1 out of every 1,900 bases in the human genome (Sachidanandam, et al. 2001). 
They are mutations which originate from the transcription of DNA. There are millions 
of SNPs registered in the main SNP database, dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). SNPs are defined as: a single base-pair at 
a specific position, which has been changed from A-T to C-G, or the opposite. Other 
examples of genetic variations are insertion/deletion or structural alterations of base-
pairs or nucleobases. SNPs of importance are those located in a coding region, resulting 
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in an altered amino acid sequence of the peptide eventually produced, or in an impact on 
the regulation of the gene. 
The human haplotype mapping project, the HapMap project, catalogues all human 
genetic variations and is freely accessible, via the internet. Haplotype is a particular 
combination of alleles along a chromosome, and an allele is one in the pair of alternative 
forms of the same gene locus on a specific chromosome (Strachan and Read 2011b) 
(2005). The variation of alleles at a locus is measurable as the number of alleles present 
in the population. The frequency of the minor allele must be greater than 1% to be 
regarded as a polymorphism (Feero, et al. 2010). 
In diseases caused by a combination of genetic and environmental factors, complex 
diseases, both common and rare alleles can be involved (Feero, et al. 2010; Schork, et al. 
2009). Association studies have been performed to identify gene loci that underlie 
complex diseases. New genotyping technique methods have made large-scale analysis 
of SNPs possible (Syvanen 2001). 
Association studies of SNPs are either in the form of Genome Wide Association Studies 
(GWAS) which measure the whole genome, or candidate gene studies which measure 
selected genes. These studies in large patient cohorts have made it possible to measure 
the associations between mapped SNPs and complex diseases (Manolio, et al. 2008). 
When an association study is planned, the decision on which SNPs to analyze is based 
on linkage disequilibrium (LD). LD is the correlation between SNP alleles; a person 
with a specific allele at one site often carries specific alleles at other nearby variant sites. 
Tag-SNPs are the variant chosen for analysis. Nearby SNPs are not analyzed if in high 
LD (>80%). The results in the form of different frequencies in patients and controls are 
compared. Odds Ratio (OR) is calculated and the p-value needs to have a stringent value 
to compensate for multiple testing (Strachan and Read 2011a). 
Today, with commercially available gene chips, it is possible to detect over 1 million 
different SNPs in a sample from a person in less than a day. 
 
2.1.1 Genetics in Sjögren’s syndrome 
Few studies on genetic variation had been published at the beginning of the work for this 
thesis, except for the MHC/HLA region. Several specific genetic polymorphisms have 
since been significantly associated with pSS in large scale candidate-gene studies 
(Nordmark, et al. 2011; Nordmark, et al. 2013; Reksten, et al. 2013) and a recently 
reported GWAS (Lessard, et al. 2013). The SNPs identified to associate with pSS are 
located in the region of MHC/HLA, in genes affecting innate immune mechanisms such 
as interferon- regulating and signaling pathways, as well as in genes of the adaptive 
immune response. 
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2.1.2 Genetics in SLE 
Familial aggregation, in the form of an affected first-degree relative, occurs in ten to 
twenty percent of SLE patients (Arnett and Shulman 1976). This indicates the 
importance of genetic factors. 
Several SLE genes have been discovered using candidate gene studies. In a meta-
analysis, 17 well-validated SNPs (P<10-5), including five with genome-wide level 
significance (P < 5 x 10-8), confirmed earlier candidate-gene studies: HLA class II 
haplotypes; interferon regulatory factor 5 (IRF5); signal transducer and activator of 
transcription 4 (STAT4); ITGAM; and B lymphoid tyrosine kinase (BLK). The genes 
are involved in B-cell signaling and development, signaling through toll-like receptors 7 
and 9, and neutrophil function (Graham, et al. 2009; Kaiser and Criswell 2010). 
GWAS have resulted in numerous SLE associated or confirmed risk genes including 
alleles in the MHC region (multiple genes), IRF5, ITGAM, STAT4, BLK, B cell 
scaffold protein with ankyrin repeats (BANK1), Programmed Cell Death 1 gene 
(PDCD1), Protein Tyrosine Phosphatase 22 (PTPN22), Tumor Necrosis Factor Super 
Family member 4 (TNFSF4), Tumor Necrosis Factor Alpha-induced Protein 3 
(TNFAIP3), osteopontin (SPP1), ATG5, XKR6, PXK, some of the Fcγ- receptors, and 
deficiencies in several complement components, including C1q, C4, and C2. These 
genes are involved in pathways of both innate and adaptive immune responses (Kaiser 
and Criswell 2010; Moser, et al. 2009). 
 
2.2 GENDER 
Autoimmune rheumatic diseases are generally more common in women than in men and 
if present during the reproductive years, require special considerations (Schuna 2002). 
This strong female dominance indicates that gender plays an important role in the 
pathogenesis of the diseases  (Shoenfeld, et al. 2012). The mechanisms are not fully 
understood. It has been suggested that hormones play an important role. Estrogen 
enhances humoral immunity and androgens and progesterone function as 
imunosuppressors (Cutolo, et al. 2004). Other possibilities could be a protective role of 
male hormones or an impact of genes on the X and/or Y-chromosomes. Other factors 
which have different effects on women and men are socio-economic factors, life-style, 
and occupation. 
2.2.1 Gender and Sjögren’s syndrome 
More than nine out of ten patients with pSS are women (Pillemer, et al. 2001). The onset 
of symptoms and an incident peak occurs around the time of the menopause suggesting 
that sex hormones have an effect. Obvious correlations such as increased disease activity 
in situations where female sex hormones have changed titers have not been noted in 
pSS, as in subgroups of patients with SLE.  
  5 
2.2.2 Gender and SLE 
The female dominance is obvious also in SLE patients, nine out of ten are women 
(Pons-Estel, et al. 2010). Increased disease activity and disease onset (Masi and Kaslow 
1978) correlate, at least in a subset of SLE patients, with the first menstruation, 
pregnancy and hormone therapy involving estrogens. The theory that there is an impact 
on genes on the X chromosome is supported by the increased risk of SLE in patients 
with an extra X chromosome, Klinefelter’s syndrome (French and Hughes 1983). 
2.3 ENVIRONMENTAL FACTORS  
2.3.1 Environmental factors and Sjögren’s syndrome  
When the genesis of pSS is discussed, it is stated that multiple environmental factors 
affecting an individual with a genetic susceptibility can lead to pSS. It has been 
suspected that infections caused by viruses, especially retroviruses are involved in the 
disease process either as triggers of the immune response or as factors in the cellular 
processes. The Hepatitis C viruses (HCV) can mimic histological changes in the salivary 
glands, which is one reason why HCV infection was added to the list of exclusion 
criteria in the current AECC. There is no convincing data to support the theory that 
viruses cause the disease, but an immune response (IgG) to Epstein-Barr Virus 
(EBV)has been demonstrated (Kivity, et al. 2014). 
No other interesting environmental factors have been noted. 
2.3.2 Environmental factors and SLE 
Several environmental factors have been noted to associate with SLE onset or flare 
(D'Cruz, et al. 2007; Simard and Costenbader 2007). Exposure to sunlight-ultraviolet 
radiation can lead to flare (Bengtsson, et al. 2002; Meller, et al. 2005; Rahman and 
Isenberg 2008). Cigarette smoking can increase the risk of SLE (Bengtsson, et al. 2002; 
Costenbader, et al. 2004). Other associated environmental factors noted in the literature 
are; environmental chemicals including silica, pesticides, mercury; infectious exposures 
especially EBV have attracted interest since patients have had serologic evidence of 
EBV infection (Harley, et al. 2006); dietary factors, one study has reported increased 
risk from ingestion of alfalfa sprout (L-canavanine is the substance responsible) 
(Akaogi, et al. 2006; Montanaro and Bardana 1991); low levels of vitamin D, observed 
in subjects with SLE (avoidance of sun exposure is a possible cause) (Kamen, et al. 
2006). 
Many drugs cause a reversible variant of SLE called drug-induced lupus; procainamide, 
hydralazine, quinidine, anti-TNFα therapy, and interferons (Araujo-Fernandez, et al. 
2014; Rahman and Isenberg 2008; Ronnblom, et al. 1991).  
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3 IMMUNOPATHOLOGY IN SYSTEMIC 
AUTOIMMUNITY 
The immune system is a defence system developed in multicellular organisms for 
protection against infections. In humans it consists of several parts which together can 
defend us against microbes such as bacteria, fungi, viruses and foreign substances. The 
immune system is divided into two major parts: the innate immune system and the 
adaptive immune system. Autoimmune diseases can develop in genetically susceptible 
individuals when exposed to specific environmental factors triggering immune 
responses. The central parts of the immune system are described below. 
 
3.1 INNATE IMMUNE REACTIONS 
The innate immune system, also called natural or native, is the defence we are born with. 
It is rapid, functions within seconds, minutes or hours after time of infection but is 
generally unspecific in its character and has no memory function. It consists principally 
of epithelial barriers, phagocyting cells and blood proteins. 
The first line of defence consists of the barriers towards our surroundings: skin and 
mucosal epithelia which prevent antigens and other harmful substances from entering 
the body. To enhance this part of our defence we have enzymes in tears and saliva, 
mucus in the airways mucosal epithelia, the cough reflex, low pH in the vagina and 
stomach acid.(Abbas 2007d) 
If microbes have entered through the epithelia, this will be recognized by the 
phagocytes: macrophages and other phagocyting leukocytes. The macrophages will bind 
the microbes to their surface receptors and molecules and engulf them. This leads to the 
macrophages becoming activated, which means that they start production of substances 
which will kill and degrade the microbes, and to the production and secretion of 
cytokines. Cytokines are proteins with a number of different effects. Initially their 
presence will attract other cells involved in the immune response, especially neutrophil 
granulocytes. The neutrophils will participate in the inflammatory process. They 
phagocytose and secrete substances which will attract even more cells to the site of 
inflammation.(Abbas 2007c) 
In viral infections cytokines called interferons are produced and, together with T 
lymphocytes and Natural Killer (NK) cells, they can kill cells infected by viruses. 
If the microbes enter the blood stream, the innate immune system has several blood 
proteins used for defence, for example the complement system through the alternative 
way. The complement factors can be activated directly by the surface of the microbes, 
bind, and binding leads to cleavage. The cleavage products coat the microbe which 
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enhances the phagocytosis, and also creates holes in the microbes, and finally 
lysis.(Elias 2008) 
 
3.2 THE ADAPTIVE IMMUNE SYSTEM 
The name adaptive immune system (AIS) comes from the mechanism of response and 
adaptation to invasion of microbes and other antigens. An antigen is a substance that 
causes an immune reaction. Another name for AIS is the Specific Immune System 
which also indicates how it works. AIS consists principally of lymphocytes and their 
secreted antibodies. It is characterized by reaction to specific antigens (specificity), the 
ability to react to a large amount of different types of antigens (diversity), and its 
memory function at repeated exposure. (Abbas 2007d) 
Specificity means that the immune response is specific for an antigen, or rather for a part 
of an antigen called the epitope. Innumerable T-cells and B cells exist with different 
structured receptors, the T- and B cell receptors. This is the basis for the diversity, 
defined as the total number of antigen specificities in the B- and T-cell repertoire. 
During an immune response, only lymphocytes which can bind to the antigen, in 
solution for B cells or presented by the Major Histocompatibility Complex (MHC) on 
the antigen presenting cells (APC) for T cells, will be activated. The lymphocytes will 
proliferate and differentiate. This increase in number of specific clones is called clonal 
expansion. The memory function consists of several components. After elimination of 
the antigen, memory cells will remain, and if new exposure occurs, the AIS will react 
much faster (secondary immune response) compared to the primary immune response. 
There are specific long-lived memory cells. These T-cells act more effectively and 
faster, and the B-cells produce antibodies with higher affinity. Also, when the antigen is 
eliminated and no activating stimuli are present the major part of the lymphocytes will 
undergo apoptosis.  
The initiation of an immune response of AIS starts with the antigen presentation by an 
APC that has engulfed and digested the antigen. Professional APCs are usually dendritic 
cells, but B-cells and macrophages can also present antigens. The APC encounters and 
engulfs the antigen at the site of infection or inflammation, and then migrates to regional 
lymph nodes and presents peptides of the antigen on its surface on the MHC molecule 
for naive T-cells. T-cells recognizing the complex of the MHC molecule and the peptide 
are activated. To start an immune response, co-stimulatory signals must also occur 
between molecules on the surfaces of the APC and T-cell (Abbas 2007a). 
Two main classes of T cells have been described; T helper and T cytotoxic cells. The T 
helper cells provide "help" for activation of many other cell-types of the immune system 
for initiating effector mechanisms, while cytotoxic T cells directly kill infected cells 
themselves. The T helper and T cytotoxic cells are distinguished by their respective 
expression of specific co-receptors for the T cell receptor; T helper cells express CD4 - 
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which is specific for binding MHC class II (present on APCs), while T cytotoxic cells 
express CD8 - which is specific for MHC class I, present on all our cells except red 
blood cells. Thus, activation of T helper cells is obtained and regulated through antigen 
presentation of immune cells, while cytotoxic T cells are activated when foreign 
peptides are presented on the cell surface of regular non-immune tissue cells. The latter 
is important for fighting intracellular pathogens such as viruses by killing the infected 
cells. 
T-helper lymphocytes become active after antigen presentation has occurred via MHC 
class II of an APC and start producing cytokines which have several effects: activation 
of themselves, activation of macrophages, and proliferation and differentiation of other 
T-and B-cells. The activated macrophages can kill and eliminate ingested microbes 
using enzymes. Several subclasses of T helper cells with different immune-regulatory 
properties have been described; Th1 and Th2, important for our defence against 
intracellular bacteria and prozoa, and helminthes respectively, as well as Th17 and T-reg 
cells. Th17 cells mediate host immunity against extracellular bacteria and fungi, while 
T-reg cells, as the name indicates, can regulate the activity of other T cells. In 
autoimmune disorders, mainly Th1 and Th17 cells have been implicated (Peters, et al. 
2011). 
While the T cell receptor remains bound on the cell surface, the B cell receptor may be 
produced in a secreted form, denoted antibodies. Antibodies can directly bind antigens 
without any presenting molecules, and thereby neutralize the antigens. This leads to 
destruction by effector mechanisms, such as phagocytosis and the release of 
inflammatory mediators. The secreted antibodies, part of our humoral immunity, are one 
of two types of responses by the AIS. Humoral immunity has been developed for 
defence against extra cellular antigens. The B-cells maturate by different steps of 
differentiation after exposure to an antigen as unmature B-cells (Carter 2006). This starts 
the differentiation into plasma cells with a high capacity of producing and secreting 
antibodies with specificity against the antigen the unmature B-cells once met. B-cells 
can bind and respond not only to protein antigens like T-cells, they can also bind lipids 
and polysaccharide antigens. Production of all classes of antibodies, Immunoglobulins ( 
Ig)M, IgG, IgA, and IgE, can only occur after exposure to an antigen and activating 
signals from T-helper-cells (Elias 2008). During the development into mature B-cells  
i.e. differentiation, mechanisms that mediate B-cell tolerance are clonal deletion and the 
negative selection and elimination of B cells that express autoantibodies with strong 
binding to autoantigens (King, et al. 1999). 
The antibodies function in several ways: They neutralize the microbes and thereby 
prevent them from entering cells; they coat (opsonize) microbes to enhance 
phagocytosis; and they bind to complement factors which will mediate lysis of the 
bound cell or pathogen.  
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3.3 AUTOANTIGENS AND AUTOANTIBODIES 
Our immune system developed to protect us from microorganisms. To defend us against 
the endless variants of pathogens, the immune system needs to be able to recognize all 
these variants (Abbas 2007a). At the same time, the immune system should not 
recognize and react against components of our own bodies ("self"). The concept of not 
generating immune responses against self-tissue is denoted "tolerance", and is an 
important feature of the immune system. In autoimmune diseases, such as most 
rheumatic diseases, tolerance is broken and the immune system starts to react to self-
tissue and/or cells. The proteins targeted are called "autoantigens".  
Why some proteins become autoantigens is not known, but it is known that tolerance 
can be broken for neo-antigens in malignancies, or when cross-reactions occur after 
infections (Levin, et al. 2002; Winter, et al. 1992). Some proteins can function as 
autoantigens both in humans and animal models, with spontaneously developing 
autoimmunity. Most autoantigens are intracellular proteins. It is probable that 
characteristics of the proteins via structural, immunological and biochemical properties 
affect the antigen presentation. Structural features found in several autoantigens are high 
flexibility, loops, and protrusion from the antigen surface (Fenalti and Rowley 2008; 
Plotz 2003). Other examples of features of autoantigens are protein modifications such 
as glycosylation and citrullination (Reynisdottir, et al. 2014; Szodoray, et al. 2010). 
Antibodies against self, autoantibodies, may occur in healthy individuals at low titers 
and are often of IgM isotype, while autoantibodies of high titers and IgG isotype rather 
occur in autoimmune diseases as a sign that breaking of tolerance has occurred.  
The role of autoantibodies in the pathogenesis is often unclear, as they commonly bind 
intracellular antigens not accessible for the antibodies. However, an active role in 
pathogenesis has been shown for anti-Ro52 in congenital heart block, as they bind cell 
surface structures in the fetal heart after passing the placenta of the pregnant mother. 
However, for clinicians measurement of autoantibodies has been a useful tool in 
diagnosis and the presence of autoantibodies has been an item in classification criteria 
and disease activity indices (Bombardier, et al. 1992; Gladman, et al. 1996; Tan, et al. 
1982; Vitali, et al. 2002).  
SLE is characterized by the production of a large set of autoantibodies targeting 
different epitopes, many of which overlap with other autoimmune diseases. 
Autoantibodies to Ro/SSA and La/SSB are commonly found in patients with primary 
Sjögren´s syndrome (pSS) and patients with SLE. Longitudinal studies have 
demonstrated that antibodies to Ro/SSA appear early, before disease onset, and prior to 
the occurrence of antibodies to double stranded DNA in SLE patients (Arbuckle, et al. 
2003; Eriksson, et al. 2011). The most frequent antibodies in SLE are ANA (96%), 
thereafter comes anti-dsDNA (78%), antiphospholipid antibodies, rheumatoid factor, 
and different anti-ENA including Ro/SSA and La/SSB (Cervera, et al. 1993). In pSS the 
most frequent antibodies are ANA anti Ro/SSA (about 50-70%), followed by La/SSB 
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(about 30-50%) and rheumatoid factor (Botsios, et al. 2011; Friedman, et al. 2006; 
Malladi, et al. 2012; Ter Borg, et al. 2010). The variation in presented figures from the 
different surveys depends on if the study is of population-based cohorts or hospital-
based case series. In the former case, it is more likely skewed towards the most severe 
forms and also more subjected to selection bias. 
 
3.3.1 ANA 
Anti-nuclear antibodies (ANA) are autoantibodies directed against antigens present in 
the nucleus and/or in the cytoplasm (von Muhlen and Tan 1995).  
ANA has high sensitivity but low specificity for both SLE and pSS since the 
autoantibodies are present in many different autoimmune diseases. Indirect 
Immunofluorescence Technique (IFL) has been used for analyses since the 1950s for 
detection of ANA, and is still a golden standard for analyses of ANA. 
3.3.2 ENA 
ENA is the abbreviation for the term Extractable Nuclear Antigens. The term refers to 
the chemical properties of the antigens. ENA consisted originally of Ro/SSA (including 
Ro52 and Ro 60), La/SSB, Sm and RNP. ELISA technique is often used today for 
analyses of antibodies against these antigens. 
3.3.3 Ro/SSA 
Both Ro/SSA and La/SSB antigens were identified by two research groups, which 
resulted in two names for each of the antigen and corresponding autoantibody which we 
use today collaterally (Aslpaugh and Tan 1976; Sestak, et al. 1987). It was later 
discovered that the Ro antigen includes a 60kD and a 52kD protein, denoted Ro60 and 
Ro52 respectively. In the 80s, it was revealed that Ro60 and La are ribonucleoproteins 
binding RNA (Wahren-Herlenius, et al. 1999), while the sequencing of Ro52 reveal that 
it shared no homologies with Ro60, and in fact was later defined as an E3 ligase 
(Espinosa, et al. 2006). All three protein are conserved i.e. present in both humans and 
animals. 
 
3.3.4 Ro60 
Ro60 has been described to function in a discard pathway of defect 5S RNA. Noncoding 
RNAs, called Y RNAs, and single-stranded ends of misfolded RNAs bind to the protein. 
After recognition and binding of the RNAs, they are targeted for degradation (Wolin and 
Reinisch 2006; Wolin and Steitz 1984). 
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3.3.5 Ro52 
The Ro52 protein consists of 475 amino acids and contains the following domains: a 
RING, a B-Box, a coiled-coil, and a B30.2 region (Ottosson, et al. 2006). The RING and 
B-box domains are zinc-binding, so called zinc-fingers.
 
Ro52 is an E3 ligase involved in the biological process ubiquitination (Espinosa, et al. 
2006). Ubiquitination is a covalent post-translational modification of proteins by the 
polypeptide ubiquitin. In this process, ubiquitin is activated by a ubiquitin activating 
enzyme (E1), transferred to a ubiquitin conjugating enzyme (E2), followed by a 
ubiquitin ligase (E3) mediated transfer of the ubiquitin from the E2 to a target protein, 
which leads either to proteolysis in the proteasome, internalization from membranes, or 
functional alteration of the ubiquitinated protein (Bonifacino and Weissman 1998; 
Weissman 2001).  
The RING domain of Ro52 is functionally active and binds the E2 conjugating enzyme 
during the ubiquitination reaction (Espinosa, et al. 2011; Espinosa, et al. 2006). 
Autoantibodies targeting the Ro52 RING domain are present in patients with lupus, and 
have been shown to inhibit Ro52-mediated ubiquitination (Espinosa, et al. 2011). The 
binding sites of the E2 ligase and Ro52-RING directed autoantibodies overlap, both 
engaging a valine in position 50 (V50) of the Ro52-RING domain. RING-binding 
autoantibodies thus abolish Ro52-mediated ubiquitination through steric hinderance 
(Espinosa, et al. 2011). In its capacity as an E3 ligase, Ro52 mediates ubiquitination of 
several members of the interferon regulatory factor (IRF) transcription factor family, 
including IRF5, and thereby regulates type I interferon and proinflammatory cytokine 
production (Espinosa, et al. 2009; Higgs, et al. 2010; Kong, et al. 2007). Autoantibodies 
directed towards the Ro52 RING domain inhibit the E3 ligase function of Ro52, and 
could therefore theoretically promote the production of type 1 interferons and lead to 
enhanced disease activity.  
3.3.6 La 
The La protein can bind to newly synthesized small RNAs, and thereby stabilize and 
protect the 3' ends of these RNAs from exonucleases. The binding to a La protein is 
necessary for the normal pathway of pre-tRNA maturation, facilitates assembly of small 
RNAs into functional RNA-protein complexes, and contributes to nuclear retention of 
certain small RNAs (Wolin and Cedervall 2002). 
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4 CLINCIAL FEATURES OF SYSTEMIC 
AUTOIMMUNE DISEASES 
The first section of this text, Systemic autoimmune rheumatic diseases, summarized the 
systemic diseases. SLE and pSS are the two diseases which resemble each other most. 
To differentiate between SLE with low disease activity and pSS, or pSS with high 
disease activity and SLE can be difficult. There are patients who, according to 
classification criteria, can be regarded as having either diagnosis.  
 
4.1 SJÖGREN’S SYNDROME 
4.1.1 Background/Summary 
Primary Sjögren’s syndrome is a systemic inflammatory autoimmune condition. It is 
named after the Swedish ophthalmologist Henrik Sjögren who defended his doctoral 
thesis in1933 with the title: ”ZUR Kenntnis der Keratokonjunktivitis sicca”. Historically 
other terms have been used, e.g. Mikulicz’s disease. 
When Sjögren’s syndrome exists as a disorder without any other rheumatic disease it is 
called primary Sjögren’s syndrome, and when it develops in patients with another 
primary diagnosis like Rheumatoid Arthritis, SLE or Systemic Sclerosis it is called 
secondary Sjögren’s syndrome. 
Prevalence figures vary around half a percent with a high female dominance. The 
etiology is mainly unknown, but it has been suggested that multiple environmental 
factors trigger an immune response in genetically susceptible individuals (Wahren-
Herlenius and Dorner 2013). In genetic studies, several single nucleotide 
polymorphisms have been significantly associated with pSS. They are located in 
chromosomal regions with loci containing genes such as MHC/HLA, Toll-like receptor 
(TLR) and type 1 IFN system genes and B-lymphocyte differentiation related genes. 
Speculations about environmental factors like viruses have long been present because of 
the similarities with pathological changes in the salivary gland tissue in hepatitis C and 
pSS. 
In pSS, inflammation results in progressive destruction of the exocrine glands, primarily 
the salivary and lacrimal glands. This leads to symptoms of dryness, mainly in the 
mouth and eyes. Patients may also experience symptoms of exocrine dysfunction and 
dryness in other areas of the body such as the skin, nose, vagina, bronchial tubes and 
gastrointestinal tract. Further, arthralgia and fatigue are prominent features of the 
disease. Signs of dysregulation of the immune system include formation of ectopic 
lymphoid tissue with lymphocyte proliferation and germinal centers in the salivary 
glands, a changed pattern in B-cell maturation and proliferation, 
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hypergammaglobulinemia and autoantibodies against the antigens Ro/SSA (Ro52 and 
Ro60) and La/SSB (Salomonsson, et al. 2003; Salomonsson, et al. 2002; Tengner, et al. 
1998).  
Extraglandular manifestations (EGM) are present in a subset of patients with pSS. This 
subset of patients is characterized by a more systemic phenotype. Examples of 
extraglandular organ involvement include hypergammaglobulinaemic purpura, skin 
vasculitis, arthritis, sensory polyneuropathy, interstitial lung disease and interstitial renal 
disease with secondary distal Renal Tubular Acidosis (dRTA). 
For classification and diagnosis the Revised American European Consensus Group 
Criteria from 2002 (AECC) (Vitali, et al. 2002) are used. A disease activity index has 
been developed for patients with EGM: the European League Against Rheumatism 
(EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) (Seror, et al. 2010). 
Treatment is symptomatic for sicca symptoms. Moisture replacement therapies and 
products that stimulate production of tears and saliva are available. In the case of severe 
EGM corticosteroids, DMARD and biologic treatment have been used. 
Lymphoma is a severe complication which a subset of patients develops. Otherwise the 
prognosis is good. Severe life threatening or life shortening organ manifestations are 
rare. The disease is mainly characterized by subjective symptoms which impair quality 
of life. 
4.1.2 Immunopathogenesis 
Focal infiltration of mononuclear cells, especially T- and B-lymphocytes in exocrine 
glands, is a hallmark of pSS. Focal inflammation starts around epithelial ductal 
structures and spreads to the deeper layer of the gland resulting in progressive 
destruction of the exocrine glands, primarily the salivary and lacrimal glands. This leads 
to symptoms of dryness, mainly in the mouth and eyes. 
The pathogenic process is complex and involves different parts of the immune system 
during the disease progression (Halse, et al. 1999; Jonsson, et al. 2011). Hypotheses 
linked together and supported by results from many investigations have formed a picture 
of the pathogenic process that leads to pSS. The current understanding indicates a 
process where environmental factors initiate disease in genetically susceptible 
individuals. The genetically dysregulated cellular pathways lead to changed activity in 
processes which increases the risk of autoimmunity. 
It is not known what initiates the process of infiltration and accumulation of 
mononuclear cells, but viral infections have been suggested. The mononuclear cells 
consist of T lymphocytes, macrophages, B-lymphocytes (plasma cells), NK cells and 
dendritic cells (DC). Epithelial adhesion molecules enable lymphocytes to adhere and 
then infiltrate the tissue. This leads to the formation of ectopic lymphoid tissue with 
lymphocyte proliferation and germinal  center-like structures in the salivary glands. 
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Inappropriate apoptosis in epithelial cells of the ducts of the exocrine glands creates 
exposure of intracellular proteins which become autoantigens. DCs play a role in the 
maintenance of tolerance to self-antigens. Loss of self-tolerance occurs and the DCs can 
be involved in several ways, for example production of IFN and antigen presentation of 
autoantigens. Patients with pSS have an IFN signature, that is, genes induced by IFN are 
activated. The presented autoantigens attract lymphocytes; some of which are 
autoreactive T-lymphocytes which can result in B-cell activation and production of 
autoantibodies. 
The increased Ig production results in hypergammaglobulinemia with a high 
sedimentation rate and the presence of the well-known autoantibodies against the 
antigens Ro/SSA (Ro52 and Ro60) and La/SSB (Salomonsson, et al. 2003; 
Salomonsson, et al. 2002; Tengner, et al. 1998). These autoantibodies are known to be 
present as signs of disease in the systemic rheumatic syndromes pSS and SLE. Recently, 
autoantibodies against the Ro52 antigen have been shown to functionally impair Ro52 
activity indicating a role in disease mechanism and activity (Ambrosi, et al. 2012; 
Espinosa, et al. 2011; Kvarnstrom, et al. 2013; Salomonsson, et al. 2005). 
The immunologic process becomes chronic and leads to inflammation involving larger 
parts of the glands and sometimes other organs. Organs containing epithelial structures 
are at risk. Increased levels of pro-inflammatory cytokines such as IL-1B, TNF-α, IL-6, 
IFN, B-cell Activating Factor (BAFF) and APRIL are present in pSS. Production of 
cytokines and kemokines leads to a positive feed-back loop that increases the 
inflammation further.  
 
4.1.3 Prevalence 
The reported prevalence in different populations varies from 0.01-0.6% (Bowman, et al. 
2004; Goransson, et al. 2011; Maldini, et al. 2014)when the AECC (Vitali, et al. 2002) 
was used. Relating to previous use of other classification criteria, varying prevalence 
figures over 5% have been reported. This is due to sicca symptoms which are common 
in the elderly with no autoimmune cause. 
4.1.4 Incidence 
Published studies on incidence are rare and have reported 1.1–5.3 cases per 100.000 
person-years (Alamanos, et al. 2006; Pillemer, et al. 2001; Plesivcnik Novljan, et al. 
2004; Yu, et al. 2013). The surveys have used different classification criteria and study 
designs, which aggravates comparisons. 
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4.1.5 Organ manifestations 
In pSS the chronic inflammation of systemic character that affects the exocrine glands 
and other internal organs, results in three types of symptoms and organ manifestations: 
general symptoms, glandular, and extraglandular manifestations.  
4.1.5.1 General symptoms 
General symptoms are common for all inflammatory rheumatic diseases particularly 
systemic diseases. They are often present long before diagnosis which can make it 
difficult to differentiate between different rheumatic diagnoses early in the disease 
process. Fatigue, fever, arthralgia, myalgia and sicca symptoms are included in this 
group. 
4.1.5.2 Glandular manifestations 
Symptoms of dryness in pSS are called sicca symptoms. The task of the exocrine glands 
is to produce lubricating secretions. Inflammation and the following progressive 
destruction of the exocrine glands lead to the sicca symptoms, particularly in the 
lacrimal and salivary glands which most often are affected. Sicca symptoms from other 
exocrine glands can occur, causing symptoms and secondary manifestations from 
different parts of the body. In the table below the main sicca problems have been 
summarized. 
Table 1: Glandular involvement, manifestations and secondary complications 
Glands Manifestations Complications 
Lacrimal glands Dry eyes/Xerophthalmia 
Keratoconjunktivitis sicca 
Corneal ulcerations 
Minor salivary 
glands, Parotid, 
Sublingual and 
Submandibular 
glands 
• dry mouth/Xerostomia 
•  enlarged Parotid,  
Submandibular swelling / 
Aseptic sialoadenitis 
Caries, ulcers, candidiasis, 
bacterial infections, 
swallowing disorders, 
lymphoma in salivary 
glands 
Small glands in the 
mucous membrane 
in the nose 
Rhinitis sicca Nasal dryness, ulcerations, 
bleeding/epitaxies 
Exocrine Pancreas Pancreatitis, lack of pancreatic 
enzymes causing diarrhea 
 
Small glands in the 
tracheobronchial 
mucosa in the 
airways 
Dryness of upper and lower 
airways 
Dry cough 
Sebaceous glands 
and sweat glands 
Xerosis/dryness of the skin Dermatitis, pruritus 
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Small glands in the 
mucous membrane 
in the genital tract  
Vaginitis sicca Dyspareunia, pruritus, 
urinary infection, 
candidiasis 
 
4.1.5.3 Extraglandular manifestations 
Most of the classical EGM are present as domains in ESSDAI. The EGM can either be 
caused by a process characterized by periepithelial lymphocytic infiltration or 
extraepithelial extraglandular involvement of B-cells with hyperactivity, antibody 
production, and immune complex formation (Tatouli and Tzioufas 2012). Classical 
EGM are arthritis, cytopenia, interstitial lung disease, interstitial nephritis with dRTA, 
liver involvement, lymphoma, palpable purpura /cutaneous vasculitis, polyneuropathy, 
and Raynaud´s phenomenon. Other examples of EGM are CNS involvement, myositis, 
and different hematological disorders.  
Arthritis 
Arthralgia is very common in pSS. When pain and stiffness in the joints are combined 
with mild swelling arthritis can be diagnosed. The arthritis is mostly mild and non-
erosive. Episodes of arthritis are common without chronic involvement of the joints. 
CNS involvement  
There is no consensus regarding the definition of Central Nervous System (CNS) 
manifestations in patients with pSS. Most common are involvements which affect 
quality of life. Characteristics of pSS CNS involvements have been described as a 
combination of migraine-like symptoms, sensorimotor deficits, coexisting 
neuropsychiatric disease and unspecific subcortical lesions (Escudero, et al. 1995; 
Soliotis, et al. 2004).  
 
Many different neurological manifestations have been reported to occur in patients with 
pSS (Soliotis, et al. 2004); for example: Motor and/or sensory deficit, 
Aphasia/Dysarthria, Seizures, Migraine, Encephalopathy, Aseptic meningitis, Cognitive 
dysfunction/Dementia, Psychiatric disorders, Myelitis, Optic neuritis and “MS-like 
syndrome”. 
CNS manifestations which are regarded as moderate activity when present according to 
ESSDAI (Seror, et al. 2010) are: “Cranial nerve involvement of central origin, optic 
neuritis or multiple sclerosis-like syndrome with symptoms restricted to pure sensory 
impairment or proven cognitive impairment.” 
“Cerebral vasculitis with cerebrovascular accident or transient ischemic attack seizures, 
transverse myelitis, lymphocytic meningitis, multiple sclerosis-like syndrome with 
motor deficit” are regarded as high activity CNS features. 
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Cutaneous manifestations 
More than half of patients with pSS have different kind of skin disorders. Most common 
is xerosis (dry skin). In patients with hypergammaglobulinemia, palpable purpura 
emerges on the front of the lower legs after physical activity. Palpable and non-palpable 
purpura are manifestations of vasculitis in small vessels. Urticarial vasculitis and 
necrotizing vasculitis of medium-sized vessels are other examples of different types of 
vasculitis in pSS. Other skin manifestations include eyelid dermatitis, pruritus, usually 
due to the xerosis, vitiligo and alopecia. Photosensitivity can develop in the subset of 
patients with anti-Ro antibodies when exposed to the sun, and this results in lesions of 
subacute cutaneous lupus erythematosus or erythema annulare (Fox 2005; Soy and 
Piskin 2006). 
Cytopenia 
Cytopenia in pSS includes anemia, leucopenia, and thrombocytopenia. Neutropenia and 
lymphopenia are the most common type of leucopenia. The severity of the cytopenia is 
based on the grade of reduction in the number of blood cells according to ESSDAI 
(Seror, et al. 2010).  
Liver involvement 
Autoimmune hepatitis and Primary biliary cirrhosis are present at higher rates in pSS 
patients than in the general population. Liver diseases are not included as a domain in 
ESSDAI (Seror, et al. 2010). Instead, these liver diseases are often regarded as co-
morbidities.  
 
Lung manifestations 
Dryness of the tracheobronchial mucosa can manifest as a dry cough. The symptoms can 
be mistaken for hypersensitivity and asthma. Inflammation in the lungs is often situated 
in the interstitium. Treatment with corticosteroids is often effective and the infiltrate 
seen on chest-x-rays looks more severe than the patient’s status. 
Lymphoma 
Lymphoma is a hematological malignancy. It is the most serious complication in pSS. 
Non-Hodgkin lymphomas develop from B-cells and the dominating types are Diffuse 
Large B-cell (DLBC) lymphoma and mucosa-associated lymphoid tissue (MALT) 
lymphoma. They are usually located in the salivary glands. Lifetime risk is estimated to 
be 5 to 15%.Tumors in the salivary glands should lead to investigation of suspected 
lymphoma. (Jonsson, et al. 2012) 
Myositis Inflammatory myopathy is rare but exists. A diagnosis of overlap syndrome or 
myositis with secondary SS should be considered when appropriate. Myalgia is very 
common and can be accompanied by weakness due to the pain. Another differential 
diagnosis is polyneuropathy affecting the muscles. 
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Polyneuropathy  
The subtypes of polyneuropathy that dominate among pSS patients are axonal 
sensorimotor polyneuropathy, pure sensory neuronopathy and mononeuritis multiplex. 
The conditions are slowly progressive and can affect survival, especially mononeuritis 
multiplex caused by necrotizing vasculitis in medium size vessels (Brito-Zeron, et al. 
2013). 
Renal involvement 
The most common form of renal involvement in pSS is interstitial nephritis which 
affects the tubular part of the nefrome leading to impaired ion exchange and systemic 
acidosis. This is known as distal renal tubular acidosis (dRTA). Patients can present with 
hypokalemic paralysis, renal calculi, or osteomalacia (Fox 2005) 
Raynaud’s phenomenon 
In patients with pSS the objective and subjective symptoms of Raynaud’s phenomenon 
are milder compared to the combination with the primary diagnosis Systemic sclerosis. 
Complications such as ulcers should result in re-evaluation of the diagnosis. 
4.1.6 Classification and diagnosis 
The current criteria, used world-wide for classification and diagnosis is the Revised 
American European Consensus Group Criteria from 2002 (AECC) (Vitali, et al. 2002). 
Since both sensitivity and specificity are very high, nearly 100%, the criteria can be used 
for diagnosis. This is stated in the original article. Both before and after the introduction 
of AECC other classification criteria have been suggested. However, none of them have 
been validated, universally accepted or used for diagnosis. 
Table 2: Short version of the revised Classification criteria for Sjögren´s syndrome 
proposed by the American-European Consensus Group 2002 
Item: Description Measured by Results 
I Subjective ocular 
symptoms  
Validated questions ≥1/3 positive response 
II Subjective oral symptoms Validated questions ≥1/3 positive response 
III Objective ocular signs Schirmer´s test 
Rose bengal score 
≤5 mm in 5 minutes 
>4van Bijsterveld’s 
score 
IV Histopathology  in minor salivary 
gland biopsy 
focus score ≥1 
V Salivary gland involvement Unstimulated whole 
salivary flow) 
Parotid sialography,  
Salivary scintigraphy,  
(≤1.5 ml in 15 minutes 
 
pathological results 
pathological results 
VI Presence of autoantibodies analysis of Ro and La Positivity Ro and/or La 
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Primary SS is defined as: the presence of any 4 of the 6 items and either item IV 
(Histopathology) or VI (Serology) must be positive or the presence of any 3 of the 4 
objective criteria items (that is, items III, IV, V, VI). Exclusion criteria: head and neck 
radiation treatment, Hepatitis C, AIDS, pre-existing Lymphoma, Sarcoidosis, Graft 
versus host disease and use of anticholinergic drugs.  
New proposed classification criteria were developed by ACR with international 
representation 2012 (Shiboski, et al. 2012). The criteria are approved by ACR. There has 
not been a broad global use of them and they are not the accepted criteria for use in 
Sweden according to e.g. Socialstyrelsen, which requires that the diagnosis in 
certifications should be based on the AECC. There are several reasons why we do not 
use them: The current criteria work well, the new criteria are not totally validated, and 
ophthalmological resources are lacking in the healthcare system to perform the optical 
staining. 
Table 3: Short version of ACR Classification Criteria for Sjögren’s syndrome from 
the Sjögren’s International Collaborative Clinical Alliance Cohort 
Features Description 
1. Positive serum anti-SSA/Ro and/or anti-SSB/La or 
Positive rheumatoid factor and ANA titer _1:320) 
2. Labial salivary gland with a focus score ≥1 focus/4 mm2 
3. Ocular staining score ≥3  
Primary SS is defined as: the presence of any 2/3 objective features in the table above. 
Exclusion criteria: head and neck radiation, Hepatitis C, AIDS, Sarcoidosis, 
Amyloidosis, Graft versus host disease and IgG4-related disease. 
4.1.7 Disease activity index 
A disease activity index for patients with primary Sjögren’s syndrome was developed by 
EULAR: Sjögren’s Syndrome Disease Activity Index ESSDAI (Seror, et al. 2010). This 
makes it possible to perform standardized evaluations of disease activity. Twelve organ-
specific “domains” were included with 3 or 4 levels depending on the severity of the 
organ manifestations. The domain weights range from 1 to 6. The maximum ESSDAI 
score is theoretically 123 but of 96 patient profiles used in the development of ESSDAI 
the highest score was 47 and mean 15. Liver diseases and conditions are not included in 
the index. Patients with a systemic disease with severe EGM score much higher than 
patients with dominance of sicca symptoms. 
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Table 4: Short version of the EULAR Sjögren’s Syndrome Disease Activity Index 
(ESSDAI) 
Number Domain Weight Description 
1 Constitutional 3 Fever, night sweating, weight loss 
2 Lymphadenopathy 4 Size and  position of lymph node, 
splenomegaly, malignant B-cell 
proliferative disorders 
3 Glandular 2 Swelling and/or enlarged salivary glands 
4 Articular 2 Arthralgia, morning stiffness, synovitits 
5 Cutaneous 3 Erythema multiforma, cutaneous 
vasculitis including urticarial vasculitis, 
subacute cutaneous Lupus and ulcers 
6 Pulmonary 5 Cough, interstitial lung disease shown by 
HRCT with shortness of breath 
7 Renal 5 Tubular acidosis with possible renal 
failure, glomerular involvement with  
possible proteinuria, hematuria or renal 
failure, histological evidence of 
proliferative glomerulonephritis or 
cryoglobulinemia related renal 
involvement 
8 Muscular 6 Myositis 
9 PNS 5 Axonal sensory or sensory-motor 
neuropathy, sensory neuropathy with 
cryoglobulinemic vasculitis, 
ganglionopathy with ataxia, 
inflammatory demyelinating 
polyneuropathy (CIDP), cranial nerve 
involvement of peripheral origin, 
mononeuritis multiplex 
10 CNS 5 cranial nerve involvement of central 
origin, optic neuritis, multiple sclerosis-
like disease , cognitive impairment 
cerebral vasculitis, seizures, transverse 
myelitis, lymphocytic meningitis,  
11 Hematological 2 Neutropenia, anemia, thrombocytopenia 
,lymphopenia  
12 Biological 1 Clonal component, 
hypocomplementemia (low C4 or C3 or 
CH50), hypergammaglobulinemia, high 
IgG,  cryoglobulinemia,  recent onset of 
hypogammaglobulinemia or recent 
decrease of IgG level  
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4.1.8 Treatment 
Treatment today is symptomatic for sicca symptoms caused by the glandular 
manifestations resulting in dryness of different surfaces of the body. As yet, no 
medication that can stop disease progression of the sicca symptoms exists. Moisture 
replacement therapies and products that stimulate production of tears and saliva are 
available. Muscarinic agonists can have an effect on both eyes and mouth, but 
limitations due to side effects impair their usefulness. In the case of EGM, 
corticosteroids, DMARD and biologic treatment can be used. No evidence based 
guidelines exist for the treatment of pSS (Ramos-Casals, et al. 2012; Ramos-Casals, et 
al. 2010). 
 
4.1.8.1 Xerostomia 
The goal of treatment is both to minimize the dryness symptoms and to prevent long-
term oral complications such as caries, candidiasis and ulcers. Saliva substitutes in the 
form of oral sprays and gels or mouth rinsing with water or oil ease the symptoms of 
dryness in the mouth and throat. More effective but only possible for patients who have 
residual salivary gland function is the stimulation of saliva flow with a secretagogue. 
Sugar-free gums and candies have an effect through mechanical and gustatory saliva 
stimulation. The muscarinic acetylcholine receptor agonist pilocarpine (Salagen®) can 
be prescribed by the patients´ physicians. It works through the stimulation of the 
muscarinic acetylcholine receptors M1 and M3 present on salivary glands, leading to 
increased secretory function Side effects associated with pilocarpine use, including 
sweating, palpitations, increased urinary frequency and flushing, limit the use of the 
agent. Several things can be done to protect the teeth. Avoidance of sugar is essential. 
Dental care with regular visits to the dentist and dental hygienists is important. Fluoride 
treatment in the form of fluoride toothpaste and extra fluoride rinses strengthens the 
tooth enamel and thereby prevents caries. Chlorhexidine mouth rinses decrease the 
amount of bacteria and can be recommended for the prevention of infections.  
4.1.8.2 Xerophthalmia/ Keratoconjunctivitis sicca 
The goal of treatment is both to minimize the dryness symptoms and to prevent 
complications such as infections and ulcers. Basic treatment is topical eye drops with 
artificial tears containing different agents (e.g. hyaluronate or methylcellulose) which 
influence the lubricating effect and how long they last. They should always be 
preservative-free. For night use lubricating ointments are used. Ophthalmic formulation 
of cyclosporine A is approved by the FDA in the USA and several other countries for 
the treatment of dry eye disease. These eye drops decrease the inflammation and thereby 
make the tears more long lasting. In Sweden this treatment is available by license. The 
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muscarinic acetylcholine receptor agonist pilocarpine (Salagen®) can also have some 
effect on the eyes. In severe forms, plug insertion or surgery of the tear duct so that tears 
cover the eye longer can be performed by an ophthalmologist. 
4.1.8.3 Exocrine dysfunction with sicca symptoms of other parts of the body 
Hair and scalp: Restriction of hair washing and the amount of shampoo used to not more 
than what is necessary. 
Nose: Saltwater (saline) rinse and nasal sprays followed by lubrication with oil or 
ointment. 
Skin: Restriction of showering and the amount of soap used, moisturizing cream 
containing a high proportion of lipids and low proportion (max 5%) of urea.  
Genital: No use of soap on mucous membrane, washing with water and oil, lubricating 
products are available to buy over the counter but oil works well. 
Gastro-Intestinal tract: Lack of pancreatic enzymes from exocrine pancreas results in 
diarrhea especially if the food contains a high proportion of fat. Capsules containing 
pancreatic enzymes can be prescribed by the patients’ physicians. 
4.1.8.4 Non-inflammatory muscle and joint involvement  
These symptoms vary over time, and Non Steroid Anti Inflammatory Drugs (NSAID) 
have a good analgesic effect and can be used when needed. Examination by a physician 
should have been performed to exclude synovitis and fibromyalgia which are treated 
differently. If NSAID are not good enough, especially if the symptoms include fatigue, 
hydroxychloroquine (Plaquenil®) has often been used, despite lack of evidence. 
 
4.1.8.5 Extra Glandular Manifestations 
The grade of evidence is low to non-existent when it comes to therapies for EGM in 
pSS. The use is based on small studies, case reports and on experience of treatment for 
clinically similar conditions in other autoimmune diseases, usually SLE or vasculitis. In 
general, corticosteroids in combination with immunosuppressive agents are the first line 
of medication. If the manifestations are refractory to standard therapies, rituximab has 
often been tried.  
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Table 5: Treatment of EGM 
Organ manifestation First and second line therapy Therapy in refractory 
cases 
Arthritis Hydroxychloroquine, 
Methotrexate 
Rituximab 
Interstitial lung disease Azathioprine Rituximab 
Renal Tubular Acidosis Bicarbonate, (potassium 
replacement) 
 
CNS involvement and 
Multineuritis 
Cyclophosamide, 
Mycophenolic Acid 
Rituximab 
Polyneuropathy IVIg, Rituximab  
Severe lymphadenopathy, 
salivary gland swelling 
Rituximab  
Vasculitis Hydroxychloroquine, 
Azathioprine 
IVIg, Rituximab 
 
4.1.9 Prognosis 
Sjögren’s syndrome is a disease that primarily affects the quality of life through 
symptoms such as fatigue, arthralgia, myalgia and sicca symptoms. Socio-economic 
consequences of the symptoms can lead to work disability and reduced social 
interaction. Lifespan is estimated as normal (Alamanos, et al. 2006) except for a subset 
of the patients. Few studies have been published on prognosis for patients with pSS 
except for those with comorbidity lymphoma. The disease process does not often lead to 
more serious organ manifestations. The most serious complication is lymphoma where 
non-Hodgkin lymphoma dominates (Theander, et al. 2004). The lifetime risk is between 
5-15%. A subset of the patients have an increased risk for lymphoma development and 
several predictors for this have been described; recurrent or permanent swelling of major 
salivary glands, systemic features, CD4 lymphocytopenia, and ectopic germinal centers 
in minor salivary gland biopsies.(Daniels 2008) 
4.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
4.2.1 Background/Summary 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by 
immunological dysregulation, especially the production of a large set of autoantibodies 
targeting different epitopes, and multiple organ manifestations. The disease is 
heterogeneous and may present in milder or more severe forms. The patients also pass 
through periods of more or less active disease, which may cause tissue damage in 
involved organs. Over time many patients develop SLE associated permanent organ 
damage. 
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The word lupus comes from Latin and means wolf. Since the Middle Ages the word 
lupus has been used to describe severe skin ulcers which today we know could have had 
different causes such as TBC, malignancies or SLE. The word Erythematosus refer to 
the colour of the skin disorders. During the 20th century immunological changes were 
discovered and the disease could be separated from other conditions. During the same 
period of time treatment became available which dramatically improved the prognosis. 
Even so, the disease still has an effect on survival but today this is also due to co-
morbidities, in particular cardiovascular diseases(Gustafsson, et al. 2012). 
The female dominance is substantial: 9 out of 10 are women and prevalence varies with 
ethnicity. In Sweden the incidence is 5 cases per 100,000 persons-years. (Stahl-
Hallengren, et al. 2000). 
Diagnosis is based on involvement of two organ systems in combination with an 
immunological disorder. The best known classification criteria is theAmerican College 
of Rheumatology (ACR) 1982 revised classification criteria for SLE(Tan, et al. 1982). 
The different items reflect possible and most frequent organ manifestations. . 
Manifestations from the musculoskeletal, hematological and mucocutaneous systems, 
heart- lung-, and kidneys are common. Validated indices that measure disease activity 
and organ damage have been developed for SLE. Most well-known are Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus Activity Measure 
(SLAM), and index of clinical disease activity in systemic lupus erythematosus-British 
Isles Lupus Assessment Group (BILAG) (Bombardier, et al. 1992; Gladman, et al. 1996; 
Griffiths, et al. 2005; Hay, et al. 1993; Liang, et al. 1989; Symmons, et al. 1988). 
Treatments depend on involved organs and severity of the flare/disease activity. Today 
corticosteroids, immunosuppressives and biologics are available.(D'Cruz, et al. 2007; 
Rahman and Isenberg 2008) 
 
4.2.2 Immunopathogenesis 
The exact process and the different mechanisms that lead to SLE are not fully 
understood. Type I IFNs (a group of cytokines) has been suggested to play a key role 
based on the observation that treatment with IFN can result in autoimmune diseases, 
including a lupus-like-syndrome (Ronnblom, et al. 1991). Further, SLE patients have an 
overproduction of Typ I IFN resulting in an activation of IFN-dependent genes, a so 
called IFN signature (Ronnblom and Eloranta 2013). This overproduction has been 
suggested to rely on activation of plasmacytoid dendritic cells (pDCs) by complexes of 
nucleoprotein autoantibodies and nucleosomes through TLRs (Finke, et al. 2009; 
Lovgren, et al. 2004; Ronnblom 2011). The nucleosomes are thought to originate from 
apoptotic and necrotic cells, of which SLE patients have a defective uptake and 
clearance. 
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Another described way of activating the pDCs is by NETs, Neutrophil Extracellular 
Traps. Dying neutrophils release NETs containing multiple components including 
histones and DNA, which can induce IFN-a production in pDCs (Garcia-Romo, et al. 
2011). The pDCs have an extremely high capacity for IFN production and can be found 
in affected tissue rather than the blood in SLE patients. 
The complement system has an impact on SLE in several ways. If activated, it can cause 
tissue damage by the formation of immune complexes, which can deposit in tissue 
especially in the kidneys. Complement factors, for example C1q, bind to the apoptotic 
material to enhance phagocytosis by macrophages. In complement deficiencies, patients 
become predisposed to infections, and a decreased capacity for clearage of apoptotic 
material develops (Sturfelt and Truedsson 2005; Truedsson, et al. 2007). C1q also 
functions as a regulator of IFN production by inhibiting pDCs (Lood, et al. 2009). 
Notably, C1q deficiency is the strongest risk factor known for the development of SLE. 
C1q functions as a regulator of IFN production by inhibiting pDCs 
Multiple changes in B-cell function and repertoire are present in SLE. The B cell 
population in SLE consists of more pre-immune B cells, memory cells, and plasma cells 
(Hostmann, et al. 2008), and the balance of plasma blasts and plasma cells is skewed 
(Odendahl, et al. 2000). The presence of autoantibodies produced by the B cells is one of 
the main characteristics of SLE. Anti-dsDNA antibodies are specific and correlate to 
disease activity. In renal biopsies the deposition of a number of other antibodies, 
including anti-Ro, anti-La, anti-C1q (a subunit of the C1 complement component), and 
anti-Sm, is known. The depositions can be in the form of immune-complexes with 
autoantigens. The deposit of immune complexes is responsible for the organ 
manifestations glomerulonephritis, arthritis and vasculitis in small arteries, followed by 
complement activation and tissue damage. Cross-reaction with proteins in the kidneys 
has also been mentioned. Hemolytic anemia and thrombocytopenia are caused by the 
binding of autoantibodies to erythrocytes and platelets, resulting in lysis (Abbas 2007b; 
D'Cruz, et al. 2007; Rahman and Isenberg 2008). In all, this loss of B-cell tolerance and 
the production of autoantibodies lead to the concept that SLE is a B-cell dependent 
disease.  
Although B cells may have a prominent role in SLE, also the T cell compartment is 
affected. Increased levels of Th17 cells with a capacity to induce inflammation, tissue 
damage and production of autoantibodies has been shown (Shin, et al. 2011), and T 
regulatory cells in SLE are fewer and have a reduced capacity of suppressing T-cell 
proliferation and cytokine production. Also, indirectly, T-cells have an impact through 
the production of cytokines TNF-α, IFN-γ, IL2, and IL-10 which stimulate B cells, 
facilitate immunoglobulin class switching, and promote production of high-affinity 
autoantibodies (Azevedo, et al. 2014). 
A number of cytokines are up-regulated in SLE, resulting in enhanced activity in some 
of their normal functions. In addition to immunomodulation, they are involved in 
systemic inflammation and end-organ tissue damage. IFNα levels are increased and the 
 26 
cytokine acts as an immune adjuvant, i.e. increases the expression of MHC class I 
molecules which enhance the antigen presentation; it increases the expression of several 
chemokines, chemokine receptors, and co-stimulatory molecules; activates NK cells and 
cytotoxic cells; promotes the differentiation/maturation of DCs;  prolongs B and T-cell 
survival; induces immunoglobulin class switch; increases the production of antibodies; 
and enhances the phagocytic capacity of macrophages (Ronnblom and Pascual 2008). 
Several B cell promoting cytokines are found in increased levels; IL-6 which enhances 
maturation of B-cells into plasma cells and increases antibody secretion; IL-10 which 
promotes antibody class-switch and B-cell activating factor (BAFF) which promotes B-
cell survival and autoantibody production. Further, SLE patients have increased levels of 
TNF, contributing organ inflammation (Ronnblom and Elkon 2010), and IL-17 which 
induces inflammation, tissue damage and again promotes production of autoantibodies 
(Shin, et al. 2011). 
 
4.2.3 Incidence 
4.2.4 Prevalence  
Incidence rates range from 1 to 10 per 100,000 person-years generally; higher figures 
have been reported from ethnic groups other than Caucasian, even an extreme figure 
from an Afro-Caribbean cohort.  
Prevalence rates generally range from 20 to 70 per 100,000 people (Pons-Estel, et al. 
2010) 
Several causes are known for the different reported figures: study design (population 
based cohorts or hospital based case series/cohorts), classification criteria, patient 
recruitment, health care system, and ethnicity, which is correlated to both genetic 
differences and socio-economic factors (Pons-Estel, et al. 2010). 
An incidence rate of 5 per 100,000 person-years has been reported from Sweden (Stahl-
Hallengren, et al. 2000). 
4.2.5 Organ manifestations 
4.2.5.1 General symptoms 
General symptoms such as fatigue, fever, arthralgia, myalgia, weight loss and sicca 
symptoms are often the first to occur. Laboratory tests show signs of general 
inflammation in the body; increased erythrocyte sedimentation rate (ESR), anemia and 
increased or decreased white blood cell count. (Bertsias 2012; Buyon 2008) 
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4.2.5.2 Mucocutaneous manifestations 
Manifestations in the skin and mucus membranes are common; more than 80% of the 
patients have experienced one or several of the associated involvements of this system. 
The most well-known are the four included in ACR 1982 revised classification criteria 
for SLE(items1-4) (Tan, et al. 1982) ; malar rash, discoid rash, photosensitivity and oral 
ulcers. The lesions can be divided into lupus specific and non-lupus specific. Non-lupus-
specific lesions can present separately or concordantly with other autoimmune 
conditions. Well-known are cutaneous vasculitis, livedo reticulitis, Raynaud’s 
phenomenon, erythema multiforme, urticaria and alopecia. The lupus-specific lesions 
are divided into three groups; acute, subacute and chronic lesions. The malar rash is an 
acute rash. It has a butterfly form, is situated over the nose and cheeks, sparing the 
nasolabial folds, and is characterized by the absence of papules and pustules. Another 
example is generalized erythema.  Acute rashes can heal without scarring. Subacute 
cutaneous lupus erythematosus (SCLE) is an example of subacute rash but is not always 
associated with SLE. It usually occurs in patients with Ro/SSA autoantibodies and is 
associated with sun exposure. The lesions start as small papules and develop into 
psoriasiform or annular form lesions. They are often located on the arms and upper 
torso. Discoid Lupus Erythematosus (DLE) is a chronic lesion. It is characterized by 
erythematous, plaque and scales, heals with scarring and is located on the head and 
upper torso. Photosensitivity means the development of rash after exposure to sunlight. 
Alopecia, loss of hair, can occur anywhere on the body. Scarring alopecia is a 
complication of DLE when it affects the hair follicles. Ulcers in the mucus membranes 
can be present in the mouth, nose and throat. They can be painless which is why it is 
important to perform an inspection. (Bertsias 2012; Buyon 2008) 
4.2.5.3 Musculoskeletal system 
Arthralgia is the most common symptom in patients with SLE. Arthritis often affects the 
small joints in the hands, but it can also occur in large joints. The arthritis is non-erosive 
in most patients. Tenosynovitis is common. Deformities have many similar features to 
those of patients with rheumatoid arthritis, such as ulnar drift and swan neck 
deformities. Inflammatory myositis can occur and sampling for creatine kinas should be 
performed, especially in cases with muscular weakness. (Bertsias 2012; Buyon 2008) 
4.2.5.4 Renal involvement 
Renal involvement is a severe organ manifestation. All patients should be checked on a 
regular basis with urine analysis for microscopic hematuria and proteinuria, since the 
manifestation does not give any subjective symptoms. If present, further analysis of 
urine sedimentation, including analysis of different types of casts, which are signs of 
renal involvement, should be done. Renal biopsy provides a histopathological diagnosis 
and classification. World Health Organizations (WHO) have classified lupus nephritis; 
Type I-normal glomerulus, Type II-mesangial disease, Type III-focal and segmental 
proliferative nephritis (less than 50% of the glomeruli are involved) Type IV-diffuse 
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proliferative nephritis (more than 50% of glomeruli are involved) and Type V-
membranous nephropathy (Churg J 1982). The classification is based on light 
microscopy. Electron microscopy can reveal minor changes and immune complex 
deposits. In 2004 the International Society of Nephrology/Renal Pathology Society 
published revised classification criteria. To summarize the most important changes, 
Class 1 is defined as minimal mesangial lupus nephritis, Class III has been divided into 
subgroups depending on whether active (Class III A) or chronic (Class III C) lesions are 
to be found. Class IV has been divided into subgroups depending on whether the 
proliferation is situated segmentally or globally (Class IV: -S(A), -G(A), etc.)(1999; 
Bertsias 2012; Buyon 2008; Weening, et al. 2004) 
4.2.5.5 Nervous system 
Both CNS and PNS can be involved. Neuropsychiatric SLE (NPSLE) was defined and 
classified by the ACR. The 19 different syndromes and symptoms included vary in 
frequency and severity. Probability of association to activity in SLE can be difficult to 
prove, especially for headaches and mood disorders. The included syndromes and 
conditions are: aseptic meningitis, cerebrovascular disease, demyelinating syndrome, 
headache, chorea, myelopathy, seizure, confusion, anxiety disorder, cognitive 
dysfunction, mood disorders, psychosis(CNS), Guillan Barré syndrome, autonomic 
disorder, mononeuropathy (single, multiplex), myasthenia gravis, cranial neuropathy, 
plexopathy and polyneuropathy(PNS)”. (Bertsias 2012; Buyon 2008)nnn 
4.2.5.6 Serositis 
Pleuritis is often painful and can be both with and without effusion. Diagnosis is based 
on typical symptoms as reported by the patient, clinical examination with rub sounds at 
auscultation by the physician, and/or signs of pleural effusion at clinical examination or 
chest-x-ray. Pericarditis has mild symptoms unless at high grade of effusion which 
affects the heart´s hemodynamic function. ECG is used to detect the condition. Echo can 
reveal the presence of effusion. If the inflammation also includes the muscular part of 
the heart, it is a more severe condition termed perimyocarditis. (Bertsias 2012; Buyon 
2008) 
4.2.5.7 Cardiovascular Disease 
Patients with SLE have a higher rate of cardiovascular morbidity and mortality. 
Cardiovascular disease is the main reason for premature mortality due to myocardial 
infarction and stroke. Smoking is the only traditional risk factor associated to 
cardiovascular events and mortality in SLE patients (Gustafsson, et al. 2009; 
Gustafsson, et al. 2012). Disease related risk factors such as antiphospholipid antibodies 
and inflammatory factors are believed to be of greater importance. Medications can 
modulate the risk, both drugs that increase (NSAID) and decrease (hydrochloroquine) 
the risk exist among commonly used medications for SLE. (Bertsias 2012; Buyon 2008) 
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4.2.6 Classification and diagnosis 
Diagnosis based on ≥2 typical organ manifestations and positive ANA or another typical 
immunological disorder at the time of diagnosis (Fries' criteria) is practical and has high 
sensitivity. No validated diagnostic criteria exist. Several classification criteria have 
been presented through the years. The most used and well- known classification criteria 
are theAmerican College of Rheumatology (ACR) 1982 revised classification criteria 
for SLE (Tan, et al. 1982). The classification is based on 11 criteria; 9 clinical and 2 
immunological. They are constructed for research purposes. A patient is classified as 
having SLE if any 4 or more of the 11 criteria are present. These criteria are cumulative.  
Table 6: Edited version of ACR 1982 revised classification criteria for SLE 
Criterion: Definition 
1. Malar rash Fixed erythema over the malar eminences 
2. Discoid rash Erythematous patches  
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight 
4. Oral ulcers Oral or nasopharyngeal ulceration 
5. Arthritis Nonerosive arthritis  
6. Serositis Pleuritis 
Pericarditis 
7. Renal disorder Persistent Cellular casts-may be red cell, hemoglobin, 
granular, tubular, or mixed 
8.Neurologic disorder Seizures 
Psychosis 
9. Hematologic disorder Hemolytic anemia 
Leukopenia 
 Lymphopenia 
Thrombocytopenia 
10. Immunologic disorder Positive LE cell  
Anti-DNA 
Anti-Sm antigen OR 
False positive test for syphilis  
11. Antinuclear antibody abnormal titer of ANA  
 
In 2012 the SLICC group (Systemic Lupus International Collaborating Clinics) 
proposed new validated classification criteria (Petri, et al. 2012). The classification is 
based on 17 criteria; 11 clinical and 6 immunological. They are also constructed for 
research purposes. A patient is classified as having SLE if any 4 or more of the 17 
criteria are present, including at least one clinical and one immunologic criterion. 
Alternatively, a kidney biopsy with histopathological changes comparable with SLE 
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nephritis in combination with presence of ANA or anti -ds-DNA antibodies is enough 
for classification. These criteria are also cumulative. 
 
Table 7: Edited version of the SLICC classification criteria for SLE 
Clinical criteria Including/ definition: 
1. Acute cutaneous lupus • Lupus malar rash 
• Bullous lupus 
• Toxic epidermal necrolysis variant 
of SLE 
• Maculopapular lupus rash 
• Photosensitive lupus  
1. OR subacute cutaneous lupus • nonindurated psoriaform 
• annular polycyclic lesions 
2. Chronic cutaneous lupus • Classic discoid rash 
• Hypertrophic (verrucous) lupus 
• Lupus panniculitis (profundus) 
• Mucosal lupus 
• Lupus erythematosus tumidus 
• Chillblains lupus 
• Discoid lupus/lichen planus overlap 
3. Oral ulcers OR nasal ulcers • Palate 
• Buccal 
• Tongue 
• Nasal 
4. Nonscarring alopecia  
5. Synovitis involving 2 or more joints OR tenderness in 
2 or more joints and at least 30 minutes of 
morning stiffness 
6. Serositis • Pleuritis 
• pericarditis 
7. Renal • Urine protein–to-creatinine ratio (or 
24-hour urine protein) representing 
500 mg protein/24 hours 
• red blood cell casts 
8. Neurologic • Seizures 
• Psychosis 
• Mononeuritis multiplex 
• Myelitis 
• Peripheral or cranial neuropathy 
• Acute confusional state  
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9. Hemolytic anemia  
10. Leukopenia 
Lymphopenia 
4,000/mm3  
1,000/mm3  
11. Thrombocytopenia 100,000/mm3  
 
Immunologic criteria Including/ definition: 
1. ANA level above laboratory reference range 
2. Anti-dsDNA antibody level above laboratory reference range (or 
2-fold the reference range if tested by 
ELISA) 
3. Anti-Sm presence of antibody to Sm nuclear antigen 
4. Antiphospholipid antibody • Positive test result for lupus 
anticoagulant 
• False-positive test result for rapid 
plasma regain 
• Anticardiolipin antibodies  
• Anti–β2-glycoprotein 1 
5. Low complement • Low C3 
• Low C4 
• Low CH50 
6. Direct Coombs’ test  
 
4.2.7 Disease activity and damage  
Measurements of disease activity and damage are essential for prognosis and choice of 
treatment. The presence of several disease activity indices reflects the complexity of 
SLE. The indices are used both in clinical practice and scientific investigations to guide 
medical decisions and facilitate comparisons. The indices have often been revised or 
modified over time for clarification and improvement, and exist in several versions. 
Three well known indices for disease activity are SLAM (Abrahamowicz, et al. 1998; 
Bae, et al. 2001; Liang, et al. 1989), SLEDAI (Bombardier, et al. 1992) and BILAG 
(Hay, et al. 1993; Symmons, et al. 1988). The index for damage used is SDI (Gladman, 
et al. 1997; Gladman, et al. 1996). 
4.2.7.1 SLAM 
SLAM is the abbreviation of SLE activity measure. It is a standardized validated index. 
The answers represent the latest month. It is weighted according to severity of the 
manifestations. If a symptom or organ involvement is absent it scores zero. The index 
consists of 24 clinical manifestations and 7 laboratory parameters to evaluate organs 
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which cannot be assessed otherwise. No immunological parameters are 
included.(Abrahamowicz, et al. 1998; Bae, et al. 2001; Liang, et al. 1989). 
Table 8: Edited version of the SLAM index.  
Constitutional Mild-moderate Severe 
1 Weight loss 1:<10% 3:>10% 
 Fatigue 1:No limits on activity 3:Functional 
limitation 
3 Fever 1:37.5 -38.5˚C 3:>38.5˚C 
Integument Mild Moderate Severe 
4 Oral/nasal ulcers, 
periungal erythema, 
malar rash, 
photosensitivity or 
nailfold infarct 
1   
5 Alopecia 1:With brushing 2:Spontaneou
s 
 
6 Erythematous or 
maculopapular rash, 
discoid lupus, lupus 
profundus or 
bullous 1esions 
1:<20%Total Body 
Area (TBA) 
2:20-50% of 
TBA 
3:>50% of TBA 
7 Vasculitis, different 
types specified 
1:<20%TBA 2:20-50% of 
TBA 
3:>50% of TBA 
Eye Mild - moderate Severe 
8 Cytoid bodies 1 3:Visual acuitv 
9 Hemorrhages in 
retina or choroidea 
or episcleritis 
1 3:Visual acuitv 
10 Papillitis or 
pseudotumor 
cerebri 
1 3:Visual acuitv 
or field cut 
Reticuloendothelial Mild Moderate  
11 Diffuse 
lymphadenopathy 
(cervical, 
axi1lary,epitrochlea
r) 
1 
 
2:>1 x 1.5cm  
12 Hepato- or 
splenomegaly 
1:Palpable only with 
inspiration  
2:Palpable 
without 
inspiration 
 
Pulmonary Mild Moderate Severe 
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13 Pleuritis 1:Shortness of breath 
or pain with exercise. 
Exam normal 
2:Shortness of 
breath or pain 
only with 
exercise, 
decreased 
breath sounds 
and dull lower 
lobes 
3:Shortness of 
breath or pain  at 
rest, decreased 
breath sounds 
and dull middle 
and lower lobes. 
14 Pneumonitis 1:X-ray infiltrates 
only 
2:Shortness of 
breath with 
exercise 
3:Shortness of 
breath at rest 
Cardiovascular    
15 Raynaud’s 
phenomenon 
1   
16 Hypertension 1:Diastolic B.P. 90-
105 
2:Diastolic 
B.P. 105-115 
3:Diastolic 
B.P.>115 
17 Peri-myocarditis 1:Pericarditis by 
ECG1 or effusion by 
echo2 
2:Chest pain 
or arrhythmia  
3:Myocarditis 
with 
hemodynamic 
compromise or 
arrhythmia 
Gastrointestinal    
18 Abdominal pain 
(Serositis, 
pancreatitis, 
ischemic bowel, 
etc.) 
1:Reported by patient 2:Limiting 
Pain 
3:Peritoneal 
signs/ 
ascites 
Neuromotor    
19 CVD3 1:TIA4 2:Multiple 
TIA /stroke, 
mononeuritis 
multiplex, 
cranial 
neuropathy or 
chorea 
3:Stroke/myelitis
, retinal vascular 
occlusion 
20 Seizure 1:1-2/month 2:>2/month 3:Status 
epilepticus 
21 Cortical 
dysfunction 
1:Mild 
depression/personalit
y disorder or 
cognitive deficit 
2;Severe 
depression or 
limiting 
cognitive 
impairment 
3:Psychosis, 
dementia or 
coma 
22 Headache including 
migraine  
1:Reported by patient 2:Normal 
activity 
3:Incapacitating 
or aseptic 
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limited meningitis 
23 Myalgia/myositis 1:Reported by patient 2: 
Some activity 
limited 
3:Incapacitating 
Joints    
24 Synovitis or 
tenosynovitis 
1:Arthralgia 2:Objective 
synovitis 
3:Normal 
function limited 
Other    
25 Own choice    
Laboratory    
26 Hematocrit(EVF5) 1:30-35 2:25-29.9 3:<25 
27 WBC6 1:2.0-3.5 x 109/L 2:1.0-2.0 x 
109/L 
3:<1.0 x 109/L 
28 Lymphocyte count 1:1.0-1.5 x 109/L 2:0.5-0.99 x 
109/L 
3:<0.49 x 109/L 
29 Platelet count 1:100-150 x 109/L 2:50-99 x 
109/L 
3:<50 x 109/L 
30 ESR7 1:25-50 2:51-75 3:>75 
31 Serum creatinine or 
creatinine clearance 
1:100-150µmol/L 2:150-
250µmol/L 
3:>250µmol/L 
32 Urine sediment    
1electrocardiogram; 2echocardiogram; 3cerebrovascular disease; 4transient ischemic 
attack; 5erytocyte volume fraction; 6white blood cell count; 7erytocyte sedimentation 
rate;  
Global visual analogue scale rating of SLE activity is included in the index. It is scored 
by the physician and the patient with values ranging from 0 to 10 which represent no 
SLE activity to highest possible activity. 
To improve the clarity and reproducibility the index has been revised as SLAM-R. It 
consists of 23 clinical manifestations and the same 7 laboratory parameters. The major 
changes are that one clinical manifestation of the eye and the item marked “other” have 
been deleted, certain manifestations have been clarified, especially the cardiopulmonary 
manifestations, and several of the manifestations have been weighted differently. 
(Abrahamowicz, et al. 1998; Bae, et al. 2001) 
4.2.7.2 SLEDAI 
The SLE Disease Activity Index; SLEDAI, is probably the most used. It measures 
disease activity over the last ten days, is a global score, and includes immunology items 
(Bombardier, et al. 1992). 
  35 
4.2.7.3 SDI 
The SLE Damage Index, SDI, measures the cumulative damage and has a prognostic 
value (Gladman, et al. 1997; Gladman, et al. 1996). 
 
4.2.8 Treatment 
Treatment of SLE depends on the severity of the disease activity/flare i.e. grade of 
inflammation and type of organ involvement. Mild activity when subjective symptoms 
dominate without objective findings in clinical and laboratory tests can be managed 
without immunosuppressive drugs. 
Musculoskeletal- and joint pain are often treated with NSAID or analgesics. Topical 
corticosteroids are used for different limited mucocutaneous diseases or in combination 
with other medical treatments. Antimalarial agents are used for both skin and joint 
involvement. Hydroxychloroquine is the most frequently prescribed and used 
medication in SLE. It prevents new flares, is used for skin and joint involvements and 
generally prolongs life. Today it is recommended that all patients with SLE should be 
treated with hydroxychloroquine if there are no contraindications. Systemic 
corticosteroids are very effective in easing symptoms and decreasing disease activity. 
The dose used is based on the severity of the organ involvement. Use of corticosteroids 
is limited by side effects such as osteoporosis, diabetes, peptic ulcers, cataract, and 
development of Cushingoid features. Today there are medical treatments that can 
prevent or at least decrease the risk of several of these side effects. Systemic treatment 
with corticosteroids should always be given using the smallest possible dose for a 
limited time. Several immunosuppressive agents are used in the treatment of SLE. The 
traditional immunosuppressives most commonly used today are azathioprine, 
methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil. Both the 
drug effects and side effects are taken into consideration when the choice is made as to 
which treatment the patient should have. Treatment with biologics has been successful 
for patients with rheumatoid arthritis but a similar positive effect has not been achieved 
for patients with SLE. Biologics used for treatment of SLE are agents that affect the B-
cells: rituximab Mabthera® and belilumab Benlysta®. Rituximab is a B-cell depleting 
therapy used off label for refractory lupus nephritis or severe CNS manifestations. 
Belilumab is the first approved medication for SLE by the authorities in about fifty years 
It is an anti BLyS-protein (B Lymphocyte Stimulator) also known as BAFF (B-cell 
Activating Factor). 
4.2.9 Prognosis 
Prognosis has improved dramatically. In the 1950s the estimated five years survival was 
less than 50% (Merrell and Shulman 1955). In 2006 Kasitano et al published figures on 
a 95% five years survival. Prognostic factors included socio-economic factors, clinical 
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manifestations, disease activity, and male gender (Kasitanon, et al. 2006). Today many 
factors and possibilities have improved: diagnostic tools, possibility for early diagnosis 
and treatment, new medication alternatives, and better social-economic status in the 
western world. In spite of this, the risk for cardiovascular disease (CVD) has not 
decreased. Gustafsson summarized the results of fourteen surveys from 1974 to 2009 on 
mortality causes. Death from CVD accounted for 6% to 76%. Death from lupus disease 
activity and infections has decreased, but not from CVD (Gustafsson 2012). In a 
Swedish study, the figure for CVD mortality between 1964 and 2004 was stable and 
accounted for about 42% (Bjornadal, et al. 2004). 
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5 AIMS 
 
General aim 
To study pathophysiological mechanisms and clinical manifestations in primary 
Sjögren’s Syndrome and Systemic Lupus Erythematosus 
 
Specific aims 
• To define the incidence rate of primary Sjögren’s syndrome (pSS) and the 
prevalence of extraglandular manifestations (EGM) at the time of diagnosis of 
pSS in a prospective, population-based manner. 
 
• To identify genetic polymorphisms of candidate genes with a role in the 
immune pathogenesis of pSS. 
 
• To identify new risk loci and single nucleotide polymorphisms associated with 
pSS in a Genome Wide Association Study (GWAS). 
 
• To investigate the expression of the target autoantigen Ro52 in salivary glands 
of patients with pSS. 
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6 PATIENTS AND METHODS 
6.1 PATIENTS 
Paper I: All consecutive patients referred to the Department of Rheumatology at the 
Karolinska University Hospital for investigation of incident pSS were included from 
January 1 2007 to December 31 2011. The referred individuals were divided into 
patients with pSS or non-pSS depending on if they fulfilled the current criteria (AECC) 
or not. Subsets of these patients were also included in the studies described in Papers II, 
III and V. 
Paper II: A total of 605 patients with pSS and 596 controls were initially included in 
the study. All patients fulfilled the current criteria (AECC) for pSS and were Caucasian 
according to their physicians. After quality control, where all individuals with sample 
genotype success rate of <90% were excluded, 540 pSS patients and 532 controls 
remained, 344 from Sweden and 196 from Norway. We eventually contributed with 79 
pSS patients from Karolinska University Hospital. Other patients originated from 
Malmö, Uppsala, and Linköping in Sweden, and Bergen and Stavanger in Norway. 
Paper III: Samples from more than 10,000 individuals (cases and controls) were 
analyzed. Quality controls were performed, sample genotype success rate of <95% were 
excluded. Relatedness within the remaining samples was determined using identity-by-
descent estimates as determined by PLINK 
(v1.07)(http://pngu.mgh.harvard.edu/~purcell/plink/). Genetic outliers were removed 
from further analysis. All patients fulfilled the current criteria (AECC) for pSS and 
originated from USA, Europe, and Australia. We initially, before quality controls, 
contributed with 99 pSS patients from Karolinska University Hospital. 
Table 9. Summary of included cases and controls in the different datasets in Paper III, 
including genotyping technique used and descent. 
 Cases (no.) Controls (no.) Genotyping Descent 
Data set 1 395 1975 Illumina Omni1-
Quad array. 
European 
Data set 2 1243 4779 Illumina 
ImmunoChip 
European 
Data set 3 1158 3071 supplemental 
custom array 
European 
Data set 4 1541 2634 Illumina 
ImmunoChip 
Non-European 
Total analyses 4337 12459   
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Paper IV: In this paper, 232 of the SLE patients managed at the Department of 
Rheumatology, Karolinska University Hospital were included February 2004 to October 
2006. All patients fulfilled four or more of the American College of Rheumatology 
(ACR) 1982 revised classification criteria for SLE (Tan, et al. 1982). 
Paper V: Twenty-eight patients from the Department of Rheumatology at Karolinska 
University Hospital, Stockholm, Sweden and the Department of Otolaryngology/Head 
and Neck Surgery at Haukeland University Hospital, Bergen, Norway diagnosed with 
pSS between the years 1992 and 2013 were included. All patients fulfilled the current 
criteria (AECC) for pSS. Twenty controls were included who originated from patients 
with sicca-symptoms who had not fulfilled the AECC critera, when evaluated for pSS. 
This was a case-control-study of 28 cases and 20 controls. 
6.2 STUDY DESIGNS 
Paper I: Population-based prospective cohort study: The patients were included 
consecutively and data was recorded at time of diagnosis. Additional data was 
retrospectively collected to the database from the patients’ records. 
Paper II and III: Multicenter case-control studies: The controls were matched for age, 
gender and geographical area. Paper V was a case-control study from two centers. The 
controls were matched for geographical area and time-period for the evaluation of 
suspected pSS. 
Paper IV: Cross-sectional study.  
 
6.3 DIAGNOSIS OF SJÖGREN’S SYNDROME 
In Papers I, II, III and V patients were evaluated for pSS, and in Paper IV patients 
were evaluated for sSS. 
To confirm if patients fulfilled the current criteria, the 2002 Revised American-
European Consensus Criteria (AECC), an examination in accordance with the items was 
performed. This included a questionnaire with validated questions from the defined 
AECC regarding sicca symptoms and exclusion criteria, a Schirmer’s test, Unstimulated 
Whole Salivary Flow (UWSF) during 15 minutes, and serological analysis of 
autoantibodies against Ro/SSA and La/SSB (this item is not included for sSS). A minor 
salivary gland biopsy was performed, if required for a complete diagnostic investigation 
of pSS, in accordance with the criteria.  
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6.4 EXTRAGLANDULAR MANIFESTATIONS, ORGAN 
INVOLVEMENTS AND INDICES MEASURING DISEASE 
ACTIVITY AND DAMAGE 
Papers I, II, III and V: No general definition of extraglandular manifestations (EGM) 
exists. In Paper I we defined EGM as typical organ manifestations from our clinical 
experience with pSS patients, and also required that they should have been described 
previously in the literature. These EGM correspond to the EGM included in the 
Sjögren’s Syndrome Disease Activity Index (ESSDAI). (Seror, et al. 2010) published in 
2010, with the addition of the liver diseases Primary Biliary Cirrhosis (PBC) and 
autoimmune hepatitis. We regarded the symptoms and organ manifestations in each 
individual as EGM of pSS if no other explanation was present. In Papers II and III a 
decision on which organ manifestations we should analyze for possible associations with 
genetic polymorphisms was made within multicenter collaborations and a study protocol 
was followed. 
To detect EGM, a clinical exam at the out patients’ clinic was performed, information 
was collected from the patients’ records, and the patients were asked anamnestic 
questions on this issue if they had an appointment, which all patients who fulfilled the 
criteria or had undergone a minor salivary biopsy were offered. 
In Paper IV features of SLE, including all items according to the ACR 1982 revised 
classification criteria (Tan, et al. 1982) and the presence of thyroid disease, were 
recorded. Disease activity was measured by SLAM (Liang, et al. 1989) and cumulative 
organ damage by the SLICC groups index SDI (Gladman, et al. 1996). 
6.5 GENERAL HEALTH AND ANAMNESTIC DATA 
Paper I, II, III: Data on general health and anamnestic information was retrieved from 
questionnaires, patients’ records and a clinical exam of those who attended an 
appointment at the out patients’ clinic. In Paper IV the same procedure was performed, 
but following a specific structured protocol. 
6.6 LABORATORY PARAMETERS 
In Paper IV, sampling followed the study protocol: Fasting blood samples were drawn 
at inclusion and routine laboratory tests and analyses of complement factors, Ig, and 
autoantibodies were performed at the SWEDAC (www.swedac.se) accredited Clinical 
Chemistry and Immunology Laboratories at the Karolinska University Hospital. IFL or 
ELISA was used for analyses of ANA, anti-ds-DNA-antibodies, anti Sm, and anti-RNP. 
In Papers I, II, III and V, in addition to autoantibodies according to item 6 in AECC 
for diagnosis, samples were taken following a decision by the physician, or retrieved 
from the patients’ records. The analysis procedures were performed as in Paper IV. In 
Paper IV, analysis of autoantibodies against the antigen Ro 52, including the epitopes 
RING and B-Box, Ro60 and La in serum, and in Paper V, autoantibodies against the 
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antigen Ro 52 in serum and urine, was performed at the Center of Molecular Medicine, 
Karolinska Institutet, at the research laboratory by ELISA (capture-ELISA in Paper V) 
technique using purified recombinant antigens.  
6.7 GENOTYPING 
Paper II: We selected 84 candidate genes: Genes in the type I IFN system; genes 
involved in the inflammatory process in minor salivary glands; genes involved in 
lymphoma development; genes associated with systemic inflammation; and genes 
identified in GWAS to associate with SLE. 
Tag-SNPs (r2=0.8 was considered as tagged) were selected by the following criteria: 
genotypes from the HapMap Caucasian (CEU) samples for SNPs with a minor allele 
frequency >5%; SNPs with an Illumina design score of >0.4; and >60 base pairs 
between SNPs. DNA samples were genotyped by the Illumina GoldenGate assay 
(Illumina Inc.). 
Usual quality controls (QC)were performed: Twenty-eight samples were genotyped 
twice by the same technique to assure high consistency, which was confirmed (100%); 
the genotype quality control threshold used in the study was a SNP call rate of >90%; a 
minor allele frequency of >1%; and a Hardy–Weinberg equilibrium in the control 
samples (P>0.001). All SNPs which did not fulfill the criteria were excluded. 1139 
SNPs out of 1261 (90.33%) remained. 
In Paper III the QC procedures were stricter, additional requirements compared with 
Paper II were: well-defined cluster scatter plots; SNP call rate >95%; sample call rate 
>95%; and p > 0.001 for differential missing between cases and controls. All SNPs 
which did not fulfill the criteria were excluded. DNA samples were genotyped by the 
Illumina Omni1-Quad array (GWAS chip), Illumina ImmunoChip, or for a subset 
supplemental custom array. Table 9 summarizes data on number of cases and controls 
for the performed data-sets analyses, used genotyping technique, and the descent of the 
included individuals. Note that subsets of cases and controls were included in more than 
one data-set. 
 
6.8 MINOR SALIVA GLAND BIOPSIES 
Paper V: When the biopsies were done for diagnostic purposes, the patients were 
offered to leave samples for research purposes to the bio-bank. The tissue samples were 
stored at -70°C in aliquots. The biopsy samples were prepared as described in the 
original manuscript and stained with Mayer’s Haematoxylin. Evaluation of staining was 
performed by three investigators (scored blindly by two) regarding: Focal infiltrates, 
whether these focal infiltrates were positively stained for Ro52 protein, and Ro52 
staining of ductal epithelium. Depending on the degree of positivity number 0, 1 or 2 
was assigned for each category, where 0 was considered negative, 1 was regarded 
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positive and 2 represented strongly positive. Focus scoring accounts focal infiltrates 
comprising of >50 mononuclear cells/4mm2 of tissue. Morphometry was added to score 
the sections by calculating the ratio-index in each gland. The ratio-index is defined as 
the total inflammatory area of focal infiltrates in the section divided by the total 
glandular tissue area (Manz, et al. 1997). 
 
6.9 STATISTICAL ANALYSES 
Characteristics of the cohort and/or included patients are described using descriptive 
statistics: For continuous variables mean ±standard deviation (SD) is used; categorical 
variables are presented as percentages. Normality of data distribution was analysed by 
the Shapiro-Wilk test. For statistical comparisons between groups the following tests 
were used: for continuous variables, Mann-Whitney U test; for categorical variables, the 
Chi-square test for 2x2 tables or Fishers exact test; and for means, the unpaired t-test. 
The Spearman correlation test was used for continuous variables. The Kruskal-Wallis 
test was used for correlation comparing several groups. 
In Paper 1 demographic characteristics such as age and gender specific information of 
the background population were retrieved from Statistics Sweden (SCB www.scb.se). 
For calculation of the 95% confidence intervals of incidence rates, the Bernoulli Model 
for categorical populations with two categories was used (Lindgren 1976). 
Calculations in Papers I and IV were performed using Graph Pad Prism version 5.01 
for Windows (Graph Pad Software, San Diego, California, USA (www.graphpad.com)) 
and Microsoft Excel 2010 (www.microsoft.com). A p-value <0.05 was considered 
significant. 
Calculations in Paper II and III were performed using: the PLINK software 
(http://pngu.mgh.harvard.edu/~purcell/plink/) for estimation of LD, calculation of ORs, 
(In Paper III for, logistic regression models) and the Cochran–Mantel–Haenszel test for 
combining the Swedish and Norwegian cohorts; the Haploview v.4.1 software 
(http://www.broadinstitute.org/haploview/) for construction of LD plots between the 
genotyped polymorphisms in the combined dataset from the controls, and to determine 
the pairwise correlation between SNPs in the combined control data and in the HapMap 
data; and the genetic power calculator Quanto for calculation of the allelic association 
power of the study using the matched case–control module for discrete traits and an 
additive inheritance mode (http://hydra.usc.edu/gxe). A p-value <0.001 was considered a 
significant association, and a p-value <0.01 was considered a suggestive association. 
  43 
7 RESULTS  
7.1 PAPER I 
7.1.1 Basic characteristics 
During the five-year study period, from Jan 1, 2007 to Dec 31, 2011, 781 patients 
(N=781) were referred to the Karolinska University Hospital for investigation of 
suspected pSS. After the investigation according to the AECC (Vitali, et al. 2002), 199 
patients (n=199; 25.5%) fulfilled the criteria (Vitali, et al. 2002) for pSS, while 582 
(781-199) did not fulfill the criteria for pSS (non-pSS). For pSS patients the age at 
diagnosis was 55.1±14.0 years (mean, SD); the majority was female, 93.5%; current 
smoking was recorded in 15.5%; familial aggregation (in a first degree relative) of pSS 
was 5.5%; and familial aggregation of autoimmune diseases was 29.5%. 
Table 10. Number of women and men with pSS presented by year 
 
women men total 
2007 25 0 25 
2008 34 3 37 
2009 37 1 38 
2010 39 4 43 
2011 51 5 56 
Summa 186 13 199 
Figure 1. Age distribution at diagnosis. 
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7.1.2 Incidence 
The mean annual incidence rate was 3.1 (95% confidence interval [CI] 2.3-4.3) cases 
per 100,000 adult inhabitants. The figures for women were 5.8 (95% CI 4.2-7.9) and for 
men 0.42 (95% CI 0.1-1.3) respectively. The female/male ratio of incident cases was 
approximately 14/1, (frequency (female) =0.93 (95% CI 0.89-0.96)).  
 
7.1.3 Investigation for diagnosis 
For patients who fulfilled the criteria (AECC) (Vitali, et al. 2002): Shirmer’s test (≤5 
mm in 5 min) was positive in 70.2%; a minor salivary gland biopsy was performed on 
85.4%; and it was positive, i.e. focus score was ≥1, in 94.1%; Unstimulated Whole 
Saliva Flow (UWSF)(≤1.5 ml in 15 minutes) was positive in 77.9%; and autoantibody 
positivity occurred in 46.2% of the patients. 
Figure 2. Overview of investigation steps and considerations. 
 
¹Basic investigation: The procedure according to the classification criteria described 
under Material and methods; ²EGM: extraglandular manifestations 
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Figure 3. Age distribution at diagnosis in autoantibody positive patients. 
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Figure 4. Age distribution at diagnosis in autoantibody negative patients. 
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7.1.4 Extraglandular Manifestations 
The subjective symptoms arthralgia (67.0%), pronounced tiredness/fatigue (60.0%) and 
myalgia (46.9%) dominated. An intermediate group of prevalence figures around 20% 
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included Raynaud´s phenomenon (20.4%), depression (19.8%) and hypothyroidism 
(18.0%). Classical EGM associated with systemic pSS were present with the following 
prevalence figures: Arthritis (13.9%), leucopenia (11.0%), lymphopenia (10.2%), 
recurrent fever episodes (7.7%), PBC (4.6%), polyneuropathy (4.1%), cutaneous 
vasculitis (3.6%), lymphadenopathy (2.1%), interstitial lung disease (1.0%) and 
lymphoma (0%). 
To identify factors that predicted EGM, we first compared autoantibody positive and 
negative patients. Autoantibody positive patients had significantly more leucopenia 
(p=0.008) and lymphopenia (p=0.05). The presence of lymphadenopathy and atrophic 
gastritis showed a tendency towards being more common in pSS patients with 
autoantibodies (p=0.07 for both).  
In the subgroups with polyneuropathy and PBC the mean age was significantly higher. 
Patients with polyneuropathy were 11.0 years older, with a mean age of 65.5 (p=0.05), 
and patients with PBC were 11.1 years older, with a mean age of 65.6 (p=0.009). 
 
7.2 PAPER II 
The Swedish and Norwegian cohorts were analyzed both separately and combined. The 
combined analysis (meta-analysis) identified associated SNPs with p-values <0.001 in 
three gene loci with no previously reported association with pSS: The early B-cell factor 
1 (EBF1) gene on chromosome 5q34; the family with sequence similarity 167, member 
A (previously denoted C8 open reading frame 13)–B-lymphoid tyrosine kinase 
(FAM167A–BLK) locus on chromosome 8p23.1; and the tumor necrosis factor 
superfamily member 4 (TNFSF4=Ox40L) gene on chromosome 1q25.1. Confirmation 
of previous association of SNP loci to pSS for IRF5/ TNPO3 gene on chromosome 
7q32.1and STAT4 gene on chromosome 2q32.3. A further eight suggested associated 
gene variants were identified. 
7.3 PAPER III 
The meta analysis identified associated SNPs with p-values < 5 x 10-8  i.e. at a genome-
wide level of significance in gene loci previously identified to associate with pSS though 
not with this grade of significance (polymorphisms in the HLA region had been 
identified previously). The gene variants were: HLA-region on chromosome 6p21 (p 
meta = 7.65 × 10−114); IRF5-TNPO3 (p meta = 2.73 × 10−19); STAT4 (p meta = 6.80 × 
10−15); IL12A (p meta = 1.17 × 10−10); FAM167A-BLK (p meta = 4.97 × 10−10); DDX6-
CXCR5 (p meta = 1.10 × 10−8); and TNIP1 (p meta = 3.30 × 10−8). A further 29 
suggested associated gene variants were identified (p meta < 5 × 10−5). 
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7.4 PAPER IV 
7.4.1 Basic characteristics 
At inclusion, patients were 48.1±14.5 (mean±standard deviation (SD)) years old and 
with a disease duration of 16.5±11.1 years (mean, SD). The age at diagnosis was 
31.6±13.0 years (mean, SD). The majority were female, 91.8%. 
7.4.2 Organ involvements and indices measuring disease activity 
and damage 
The most common organ manifestation was arthritis, observed in 86.1% of the patients, 
followed by photosensitivity (68.5%), and malar rash (53.4%). The frequency of 
autoantibody positivity for ANA was 99.1%, and for anti-ds-DNA 68.5%. The mean 
number of fulfilled ACR classification criteria in the cohort was 6, the mean for the 
SLAM activity score was 7, and the mean of the cumulative organ damage index SDI 
was 1. 
7.4.3 Correlation between autoantibodies and disease activity 
Ro52-RING antibody levels were associated with higher disease activity measured by 
SLAM. The analysis was made by categorizing the patients into four groups (quartiles) 
depending on their autoantibody level. The difference in clinical activity observed for 
Ro52-RING antibody levels had a p value of 0.04 (Kruskal-Wallis). No other 
association between any of the autoantibodies and disease activity was found. 
7.4.4 Correlation between autoantibodies and clinical/laboratory 
manifestations 
Anti-Ro52 antibody levels correlated with more of the investigated variables than did 
Ro60 and La autoantibodies. The condition of sSS and the items for diagnosis, as well as 
the degree of decreased production of saliva and tears, associated with Ro52 and to 
some extent with Ro60 and La antibodies. Ro52 antibody levels also correlated 
positively with the sedimentation rate, Ig levels, and with decreased count of both 
leucocytes and lymphocytes. We found no correlation between the autoantibodies and 
any individual severe form of organ manifestation. 
7.5 PAPER V 
Ro52 was highly expressed in all the focal infiltrates in pSS patients. Significantly 
higher degree of Ro52 expression in ductal epithelium was observed in the patients 
compared to the controls (p<0.03). The degree of ductal epithelium expression of Ro52 
correlated to the level of inflammation (Spearman r=0.48, p<0.0120). No secreted Ro52 
protein could be detected in serum or saliva samples of these individuals. 
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8 DISCUSSION 
8.1 PAPER I 
8.1.1 Incidence 
In this prospective study we found an annual incidence rate of pSS in the Karolinska 
University Hospital catchment area of 3.1 cases per 100,000 person-years. To the best of 
our knowledge, no other population based prospective study of incidence using the 
current criteria exists. Three other publications on this topic have published similar 
figures (1.1–5.3 cases per 100.000 person-years), but the surveys have other study 
designs and criteria. Plesivcnik et al (Plesivcnik Novljan, et al. 2004) observed an 
incidence rate in Slovenia of 3.9 cases per 100,000 inhabitants (95% CI 1.1-10.2) using 
the European classification criteria. Pillemer et al (Pillemer, et al. 2001) observed an 
incidence of 3.9 (95% CI 2.8-4.9) per 100,000 in a retrospective study of physician-
diagnosed pSS in Olmsted County, Minnesota, and Yu et al (Yu, et al. 2013) published 
figures of 10.6 (95% CI 9.9–11.4) from Taiwan using the present AECC. We believe the 
true incidence may be slightly higher than our findings. The difference, in addition to 
other criteria and study designs, may be explained by potential selection bias, and 
possibly that private rheumatologists have seen and diagnosed pSS patients: We believe 
their patients represent less than five percent of the total number, based on private 
rheumatologists limited capacity to accept new patients, in combination with the fact 
that the Department of Rheumatology at Karolinska has accepted to perform 
investigations for all referred patients with suspected pSS. In addition to study design 
and used classification criteria, other factors which influence the pattern of referral will 
have an effect on the calculated figures of incidence rate we have presented. People with 
mild symptoms can remain undiagnosed, some individuals may never contact their 
doctor regarding their symptoms, and for some patients the doctor performing the 
primary investigation may have chosen not to refer a patient that would have fulfilled 
the criteria. We believe there is a growing awareness of pSS in the general population in 
Sweden due to more easily available information from patient organizations and via the 
internet. As a result, more patients probably contact their doctors, even with milder 
symptoms. The examples can have both increasing and decreasing impact on incidence. 
8.1.2 Extraglandular Manifestations 
The presence of EGM in our cohort is comparable to other recently published studies, 
although figures for the presence of autoantibodies and more severe EGM such as lung 
and neurological diseases are lower in our cohort. We attribute the differences to the 
following: The fact that our cohort consists of incident cases; we expect development of 
more EGM over time and a follow-up in our cohort may result in EGM in range with 
other cohorts of established pSS; and a different study-design, i.e. population-based or 
hospital case-series, prospective or retrospective. In hospital case-series, the patients are 
skewed towards the most severe forms of the disease. We wanted to compare our results 
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with those from other population based surveys. We performed several data base 
searches in PubMed and found several published population based studies on pSS but 
few on EGM generally that would match for comparison. Friedman et al. (Friedman, et 
al. 2006) was the only matching survey with the criterion of population-based surveys of 
EGM fulfilled. Their published figures were generally lower for all EGM except 
polyneuropathy, but data were missing for liver diseases.  
Notably, lymphoma is an EGM which is typically known to debut several years after the 
pSS diagnosis, explaining why no patient in our cohort had lymphoma, since they were 
included at the time of diagnosis, and preexisting lymphoma is an exclusion criterion for 
pSS. In our cohort, five individuals were excluded from pSS diagnosis due to 
preexisting lymphoma. 
We believe our low figures of EGMs represent a low grade of selection bias, and that 
they are truly representative for pSS in the population as defined by the AECC criteria. 
 
8.2 PAPER II 
The three new identified gene loci with SNPs associated with pSS, EBF1, FAM167A-
BLK and TNFSF4, are all involved in B-cell development and activation. Two of them 
have previously been associated with other autoimmune diseases, FAM167A-BLK and 
TNFSF4. EBF1 had not previously been associated with several autoimmune 
conditions, but with acute leukemia of B cell origin. However, despite no previous 
association for EBF1 with autoimmune diseases, it is obvious that the gene variation 
relates to the other novel discovered gene variations in FAM167A-BLK and TNFSF4, 
via the common factor involvement in one of the steps of the B-cells development from 
immature forms to effector cells, plasma-cells. The possibility that other gene variations 
affect cells in the immune system, but not previously have been associated with 
autoimmunity, should be considered in the future search for associated gene variations.  
The novel results of association with gene variations in EBF1, FAM167A-BLK and 
TNFSF4 support the opinion that pSS is a B-cell driven disease, to an even higher 
degree than in SLE, in view of the additional association with EBF1. The involvement 
of associated gene variants with functions in the immune system, including previous 
findings of associations with IRF5 gene variants, strengthens the importance of 
autoimmune mechanisms in the pathogenesis of pSS and the close relationship with 
other autoimmune diseases, in particular SLE. All associated novel gene variants, except 
EBF1, and all confirmed gene variants, IRF5 and STAT4, had previously been 
associated with SLE. Patients with SLE and pSS have similar and different features in 
their disease phenotypes. For physicians it can be difficult to differentiate between the 
diagnoses, especially at disease onset. In other situations the difference is obvious, 
especially in patients with severe organ manifestations and presence of specific 
autoantibodies. To further investigate the genetic background to these similarities and 
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differences in the diseases phenotypes, functional studies must be done. Association 
studies can be the first step in the process of understanding pathogenesis and disease 
mechanisms. Though, the actual effect of the gene variation in form of increased/ 
decreased production of peptides from the protein-coding gene or altered effect of the 
peptides needs to be investigated by functional studies. This future perspective describes 
the next step in how we must form the coming study designs for our work.  
The chosen threshold level for associated gene variants was p<0.001 and for suggested 
associated gene variants p<0.01, was decided in comparison with other publications. At 
that time other candidate-gene studies had been published with the same association 
significance level. The identified gene variants have later been confirmed for pSS by 
GWAS using the genome-wide level significance (p < 5 x 10-8). We chose to not use 
Bonferroni correction in our candidate gene study, which often is used to counteract the 
problem of multiple comparisons. The method is regarded as the simplest and most 
conservative of available alternative tests for correction in multiple testing. However, we 
still found it too strict for our candidate-gene study. If the Bonferroni correlation had 
been used, several of the associated gene variants had not been regarded as significantly 
associated. To perform a Bonferroni correction, the calculated p value is divided by the 
number of comparisons (i.e. tests/SNPs). Bonferroni assumes that all analyses are 
independent of each other. This is not the case of SNP analysis, since several SNPs have 
high LD. Additionally; the selected genes for analyses are not independent on each other 
since they have common biologic involvement in a specific disease, in this case pSS. 
8.3 PAPER III 
This is the first GWAS of pSS, and both novel gene loci associated with pSS were 
identified and previously associated gene loci were confirmed. More than 10,000 cases 
and controls were genotyped. The different used technique for genotyping is 
summarized in Table 10. Note that subsets of both cases and controls were included in 
more than one analysis. This large numbers of patients and controls, well matched for 
descent, secured the possibility to achieve a valid result. The associated genes with 
variations have their normal function within the immune system: STAT4, IRF5, and 
GTF21 are transcription factors; IL12A is a cytokine; BLK is a B-cell kinase; and 
CXCR5 a chemokine. Again, this highlights the importance of a normal function of the 
immune system to prevent pSS development. It is also very interesting that no 
association with tissue specific gene variants were identified. The question why exocrine 
glands are the target organs, when no genetic association with these organs can be 
identified, must lead us to investigate more environmental factors, as triggering factors 
for the pathogenesis.  
In patients with rheumatoid arthritis, autoantibody (ACPA) positive and negative 
patients, have different associated gene variants, mainly in the HLA region (Padyukov, 
et al. 2011). In line with this finding, we should consider possibility of similar gene 
association pattern in pSS. In future analyses, stratification by autoantibody status would 
be interesting in analysis of genetic associations in pSS. 
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Another GWAS in pSS originating from China was published at the same time as ours 
(Li, et al. 2013). In the study, 597 pSS cases and 1,090 healthy controls were genotyped 
using Affymetrix® genome wide arrays. The results were substantially different. A 
novel gene loci was identified, not involved in immune response (GTF2I at 7q11.23 p 
meta = 1.31 × 10-53)). They also confirmed some previously reported associations in our 
GWAS with pSS cases of European descent, STAT4, TNFAIP3 and the MHC. Possible 
explanations for the differences can be: Other genetic variations in the analyzed Chinese 
cohort compared to the European descent cohort and the difference in number of 
included cases and controls, thereby less power to identify associated gene variants in 
the Chinese cohort.  
In our GWAS >60% of the analyses were performed by the Illumina Immunochip, 
which is not a GWAS technique chip. However, it includes most genes involved in 
autoimmune diseases. The survey may be regarded as a GWAS due to made 
comparisons between the subsets of the analyzed data sets, the well-characterized 
patients, and the European descent secured by the PLINK technique. We believe the 
result would have been essentially the same if all patients had been genotyped with the 
GWAS technique, and that identification of additional loci will depend mostly on 
expanding the patient and control cohorts.  
 
8.4 PAPER IV 
8.4.1 Correlation between autoantibodies and disease activity 
The novel finding in this study is the observation that only those antibodies targeting the 
RING domain of Ro52 were associated with higher disease activity in patients with 
SLE. None of the other autoantibodies we focused on in this study: Ro, La, and the more 
recently discovered subset of autoantibodies against the B-box epitopes of Ro52 showed 
this association. The RING domain is the enzymatically active part of the Ro52 protein, 
and contains the E3 ligase activity. This is interesting since anti-RING antibodies have 
been shown to bind, and inhibit, this function, and thereby inhibit the degradation of 
transcription factors for type 1 interferons (Espinosa, et al. 2011)known to mediate 
higher disease activity in SLE. Ro52 ubiquitinates and down-regulates the activity of 
IRF5 and IRF3 transcription factors. Anti-RING antibodies could thus directly 
contribute to disease pathogenesis in SLE through inhibition of Ro52 biologic activity in 
its capacity as a negative regulator of type 1 interferon production, leading to increased 
IFN-a and -b levels. Increased levels of type 1 interferons are present in a substantial 
number of lupus patients, and they increase during flares. 
Our choice of SLAM, instead of SLEDAI which is more commonly used for 
measurements of disease activity in SLE, is based on the fact that SLAM does not 
include items with autoantibodies. Thus, a bias when analyzing correlations with 
autoantibody levels is avoided. SLAM is also a well-validated index for measurement of 
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disease activity in SLE and takes both subjectivity and severity into consideration. 
Studies in other, similarly well-characterized cohorts are desirable for confirmation of 
our observation that SLE disease activity correlates with Ro52-RING antibodies. It 
would also be desirable to perform a study of RING- autoantibodies in a cohort of pSS 
patients. Presence of Ro-antibodies and/or La antibodies is one of the items in the 
diagnosis AECC for pSS. Today a validated disease activity index for pSS is available, 
the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) (Seror, et al. 2010). 
However, the index is not yet well established in clinical use and it measures more 
severe form of EGM in pSS. A multi-center study could be a future possibility to have 
enough patients for such an investigation.  
 
8.4.2 Correlation between autoantibodies and clinical/laboratory 
manifestations 
We confirm that SLE patients with La and/or Ro autoantibodies have less severe disease 
where skin and joint manifestations dominate, a clinical feature also present in pSS with 
EGM. This finding adds another example of similarities between pSS and the subset of 
SLE patients with sSS. We noted the correlation between Ro52 autoantibodies with sSS 
and the items for diagnosis of sSS in the current diagnostic and classification criteria. Ro 
autoantibodies correlated with more variables than any other autoantibody. We could 
not confirm that the process of epitope spreading would lead to correlation with other 
symptoms of sSS and other of the studies autoantibodies. To further analyze this we 
would need to do a follow-up study and re-measure autoantibodies and re-evaluate the 
different items included in the classification criteria AECC. Ro autoantibodies are one of 
the first autoantibodies to appear in the SLE development, often before onset (Eriksson, 
et al. 2011). The very presence of these autoantibodies can contradict a more severe 
disease. This could mean that it is possible early after diagnosis of SLE in absence of 
negative predictive factors chose less strong medications. This is an important matter 
since side-effects of medication have previously been an important problem for patients 
with SLE. Even if we have more treatment alternatives to offer today, even biologics, 
severe side-effect will be a matter for worry among patients for a long time.  
 
8.5 PAPER V 
The expression of Ro52 was observed in ductal epithelium in saliva gland tissue 
deriving from minor saliva gland biopsies. These biopsies had been performed if 
required for a complete diagnostic process in accordance with the present classification 
criteria for investigation of suspected pSS. The expression was present in both cases and 
controls but in a significantly higher degree in the cases (patients) compared to the non-
pSS controls (p<0.03). 
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The cases consisted of patients who fulfilled the classification criteria and the controls 
did not. The controls were thus not healthy individuals but patients with sicca symptoms 
of a degree that made a physician decide to perform a minor salivary gland biopsy. The 
impact of this background information is not known. It could be possible that expression 
of Ro52 in ductal epithelium in saliva gland tissue, at least in a low degree is a found 
present in subsets of the population over time. An investigation of healthy controls, 
without sicca symptoms, is required for more information in this matter. 
That the degree of ductal epithelium expression of Ro52 correlated to the level of 
inflammation (Spearman r=0.48, p<0.0120) in the tissue, supports that a high degree of 
expression of Ro52 is a part of the disease pathogenesis. Correlation of Ro52 expression 
has earlier been demonstrated in SLE patients from skin lesions (Oke, et al. 2009). 
Expression and upregulation of Ro52 have been demonstrated in both SLE and pSS and 
in both diseases a correlation with inflammation. This supports Ro52 as a general target 
in autoimmunity. It also is an example of similarities of the diseases. 
We believe that the upregulation of Ro52 occurs early in the pathogenic autoimmune 
disease and that it can lead to breaking of tolerance in genetic susceptible individuals. 
Autoantibodies can be a consequence of this expression. If so, the pathogenic process is 
ongoing for a very long time. The presence of autoantibodies has been shown to occur 
many years before diagnosis, and if the expression of Ro52 appears even earlier, the 
pathogenic process is expected to start decades before diagnosis.  
The ELISA analyses could not detect Ro52 in saliva or serum from neither cases nor 
controls.  This suggests that Ro52 is not a secreted protein, and that the antigen exposure 
takes place in the tissue of the target organ. 
If possible it would be interesting to analyze Ro52 in salivary gland tissue from SLE 
patients, healthy controls and sSS to other autoimmune diagnosis in addition to SLE. 
This could further reveal the role of Ro52 in pathogenesis of autoimmunity. 
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9 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
This thesis has focused on pathogenesis and descriptive studies of pSS and SLE. For 
pSS the studies have included epidemiology, genetics, and histopathological 
mechanisms. For SLE we focused on immunological mechanisms in the form of 
autoantibodies. The main observations include: 
• The annual incidence rate of pSS in the Karolinska University Hospital 
catchment area was 3.1 (95% CI 2.3-4.3) cases per 100,000 adult inhabitants. 
The female/male ratio of incident cases was 14/1, (frequency (female) =0.93 
(95% CI 0.89-0.96)). 
• Lower figures for severe EGM for incident pSS, and lower frequency of 
autoantibodies including ANA, anti-Ro/SSA and anti-La/SSB that previously 
described for pSS was observed in this population based cohort. 
• Candidate-gene and GWAS studies clearly indicate a similar background in 
genetic mechanisms in autoimmune diseases, in particular for pSS and SLE. 
The genetic variances demonstrate the importance of B-lymphocytes in the 
mechanisms of pSS pathogenesis. 
• RING-autoantibodies are correlated to higher disease activity in SLE patients 
which support the importance of Ro52s function as an E3ligase and its clinical 
implications. 
Future perspectives 
More epidemiological studies on incidence rate in population-based prospective studies 
of pSS are desirable to confirm our figures. 
A follow-up study of EGM frequencies in the incident pSS cohort to confirm the 
expected development is planned.  
Functional studies of the consequences of SNPs in associated genes are necessary to 
further reveal how these gene variants enhance the risk for pSS development. 
Further studies on the RING-autoantibodies should be performed in patients with other 
autoimmune diseases. 
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